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Abstract: Psychosis, as seen in Schizophrenia and Schizoaffective disorder, is the most 
debilitating of psychiatric dysfunctions, affecting more than 21 million people per year 
globally.     
Adverse childhood experiences (ACE) and psychosis have significant correlation. 
We used the ACE Questionnaire (ACEQ) in this study to evaluate childhood trauma. 
There are, however, many instruments used to assess ACEs. Instruments vary and are 
used at the discretion of the study facilitator to meet the perceived needs of the study. We 
assessed the prevalence of the instruments used to assess childhood trauma in individuals 
with psychosis via a systematic review.   
BDNF and β-catenin are critical in early and continued neuronal development and 
proliferation, particularly in the hippocampus (Hpc). Cortisol, well-known for being the 
major stress hormone, and is known to damage to Hpc neurons in chronic stress. In this 
study serum BDNF, β-catenin and cortisol will be measured in patients with a diagnosis 
of Schizophrenia (Sz) or Schizoaffective disorder (SzA) and evaluated for correlation 
with their respective ACEs scores.  
We had a sample size of 11 patients (4 Female, 7 Male) with diagnosis of either 
Sz or SzA (Sz=2M, SzA=4F, 5M). All were administered a Structured Clinical Interview 
for DSM-5 - Clinician’s Version (SCID-5-CV) to confirm diagnoses, the ACEQ, and a 
blood draw to evaluate serum for biomarkers.  
We found a significant negative correlation (p=0.027) between cortisol levels and 
higher ACEQ scores in our sample population. β-catenin and BDNF demonstrated 
downward linear trends relative to higher ACEQ scores, which with increased power 
could show significant correlation. 
170 studies met criteria for the systematic review, 24 instruments were isolated 
from those studies. Of those 100, (58.9%), of the studies isolated utilized the Childhood 
Trauma Questionnaire (CTQ) to assess adverse childhood experiences in patients with 
psychosis. 
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For millennia, severe mental illness has existed outside of the scope of science. Often it 
was associated with religious persecutions, demonic possessions, moral failures of the individual 
or one of their progenitors. As understanding progressed, dementia praecox, or dementia of the 
young, became the formal predecessor of the modern diagnoses of Schizophrenia Spectrum 
Disorders (SSD) (Jablensky, 2010).  
Schizophrenia spectrum disorders (SSD) encompass psychotic disorders including both 
Schizophrenia and Schizoaffective Disorder. The criteria are defined by the Diagnostic and 
Statistical Manual of Mental Disorders, 5th Edition (DSM–5). SSD are diagnosed when psychotic 
symptoms persist for longer than six months. These diagnoses require two of five symptom 
criteria. There are four positive symptom categories. They are delusions, hallucinations, 
disorganized speech, disorganized or abnormal behavior. Delusions are fixed false beliefs and 
exist outside of the cultural norm for the individual. Hallucinations are experiences of the senses 
without corresponding external stimuli, most common are auditory and visual, with tactile and 
olfactory occurring less frequently. These must exist outside of individual cultural norms. 




For example, an individual may live in a culture in which spiritual or religious visions are    
considered normal and these experiences would then not fall within the definition of a visual 
hallucination. Disorganized speech may be present in many forms, loose associations, tangentiality or 
circumferentiality. Tangential speech can present similarly to the word salad seen in Wernicke’s 
aphasia, patients are responsive and fluent but seemingly nonsensical (Kuperberg 2010) or unrelated 
to the topic of the conversation. Disorganized or abnormal behavior may consist of unpredictable or 
inappropriate action or catatonia. Negative symptoms include inappropriate or absent affect, 
avolition, alogia, anhedonia, apathy, and aversion to regular social interaction. These negative 
symptoms are often the first symptoms to present (Correll & Schooler, 2020). Schizoaffective 
Disorder differs from Schizophrenia in that patients may have either a diagnosis of Major Depressive 
Disorder (MDD) or Bipolar Disorder (BD) I or II, in addition to psychotic symptoms that occur when 
they are not actively experiencing a depressive, manic, or hypomanic episode as defined by the DSM-
5. Both positive and negative symptoms contribute to the significant hardship in the maintenance of 
social functioning for individuals afflicted with SSD, many of whom may have been thriving prior to 
onset, causing major personal and familial upheaval. Because of the major social toll of this disease, it 
is important that scientists continue to research its neuropathologies.  
As information has become more available, our understanding of the etiology of these 
diseases has become more, rather than less, complicated. There have been many associated genetic 
variants identified, but so far none of these genes have been sufficient to define the disease 
(Vereczkey & Mirnics, 2011).  Increasingly, the importance of various environmental components 
has been validated. Among the most important is the association of adverse childhood experiences 
(ACEs). In 1998 the clear and long-lasting impact of ACEs was validated in the sentinel study by 
Felitti et al. This study, and the development of its associated ACE Questionnaire (ACEQ), helped 
incorporate childhood trauma assessment as an aspect of standard medical care in the United States. 
The ACEQ is a ten-point self-reported diagnostic of early/childhood traumatic experiences. It has ten 




either/or one-point questions to determine exposure to psychological, sexual, and physical abuse, 
parental mental illness or suicidality, neglect, and incarceration of a primary family member (Felitti et 
al., 1998). The study found that patients that reported an ACEs score of four or greater demonstrated 
a four-to-twelve-fold increased risk for negative health outcomes. Outcomes such as alcoholism, drug 
abuse, and suicidality. They also demonstrated a four-fold increase in risky sexual behaviors and 
obesity. The criteria defined by this study established a series of negative outcomes resulting from 
ACEs, increasing in severity from the bottom up. This was conceptualized as “The ACEs pyramid”. 
The potential outcomes are defined from bottom to top as: social, emotional, and cognitive 
impairment, adoption of health-risk behaviors, disease, disability, and social problems, culminating in 
premature death. 
  
Figure 1. ACES Pyramid and Intergenerational and Social Location (RYSE 2015). 




The study demonstrated significant correlation of ACEs and mental illness. Indicated by 
increased suicidality, hallucinations, and associated antipsychotic prescription with an ACE score of 
four or greater (Felitti et al., 1998). These insights spurred extensive research regarding the 
development and onset of Schizophrenia and its comorbidity with ACEs. There is now a significant 
body evidence to support the correlation of ACEs and the age of onset and development of 
Schizophrenia (Varese et al., 2012, Popovic et al., 2019). Correlation of ACEs and SSD has been 
demonstrated in diminished or modulated levels of cognitive function in first-episode psychosis 
patients and healthy controls both with a history significant for ACEs (Sideli et al., 2014). In a 2017 
study by Vallejos et al., 63% of male patients diagnosed with Schizophrenia had an ACEs score of 
four or higher on the scale of zero to ten.   
These formative traumatic experiences leave lasting changes in both gray matter volume 
(GMV) and neurochemical hormone production. Our study investigates Brain-derived neurotrophic 
factor (BDNF), β-catenin, and cortisol correlated with the severity of ACEs scores in patients with 
SSDs.  BDNF, β-catenin, and cortisol have been chosen for this study because of their relevance to 
proper nervous system health and maintenance, as well as previously established relationships with 
SSDs and ACEs. 
BDNF is a neurotrophin and key moderator in the function of actively firing neurons. It is 
believed to be critical in the dendritic spine remodeling associated with learning and memory via 
long-term potentiation (LTP) within the hippocampus (Hpc) (Borodinova & Salozhin 2017). This is 
the area of the brain strongly associated with learning and memory. BDNF functions to support many 
areas of the brain, including the prefrontal cortex (Pfc), the area in charge of executive function and 
decision-making (Chang et al., 2018). It is involved in axonal guidance and elongation, dendritic 
collateral branching, and synaptogenesis (Yoshii & Constantine 2010, Figurov et al., 1996). BDNF is 
also an important moderator of neuronal health via neurogenesis and plasticity. Because BDNF is 
associated with neurogenesis and dendritic remodeling, it has been a target of interest for stress and 




trauma-related changes in neuronal function, physiology, and in psychological disorders (Theleritis et 
al., 2014). BDNF levels have been shown to be decreased in patients with Schizophrenia (Fernandes 
et al., 2015), making it an important potential biomarker for SSDs.  
β-catenin is a highly conserved protein associated with the canonical Wnt/β-catenin signaling 
pathway during embryonic and fetal development (Medina et al., 2018). It serves two primary 
functions in adult physiology: cell adhesion and as a genetic transcription factor. Notably, in the 
brain, β-catenin has been shown to function in regulating neuronal development and differentiation of 
nerve cells (Teo et al., 2018). It functions in synaptic stabilization and neuroplasticity in the formation 
and maintenance of memory within the Hpc (Teo et al., 2018). β-catenin has also been shown to have 
important maintenance function in dendritic arborization by acting as a cytoskeletal element within 
the Hpc that supports synaptogenesis (Yu & Malenka 2003). Because of these important supportive 
functions in the brain, there has been some research on β-catenin in relationship to neurological 
disease. As early as 1998, Cotter et al. found a decrease in the concentration and distribution of β-
catenin in Hpc of postmortem Schizophrenia patients compared to controls. It is however, more often 
studied in relation to its association with oncogenic processes in cancers, which makes it an exciting 
and more novel aspect to this study. 
Cortisol is a glucocorticoid, or stress hormone, and is extremely important to species 
maintenance and survival during periods of external and internal stress stimuli. Cortisol can either 
induce or inhibit gene transcription and acts to modulate body functions to support endurance during 
stress (Teo et al., 2018). Prolonged cortisol exposure can be detrimental, causing changes in neuronal 
plasticity or loss of viability (Kim et al., 2002). Obtaining a cortisol level is of particular importance 
when looking at neurodegenerative disease or dysfunction because glucocorticoids modulate protein 
transcription, including BDNF and β-catenin, which are vital to neuronal health (Suri & Vaidya 
2013). In studies with mice, chronic stress increased levels of glucocorticoid production resulting in 
decreased β-catenin expression in the Pfc and Hpc as well as the degeneration of Hpc neurons (Teo et 




al., 2018). Studies measuring cortisol levels in patients with Schizophrenia indicated a statistically 
significant increase in fasting cortisol levels in patients with Schizophrenia versus controls (Ryan et 
al., 2003, Thakore et al., 2002). However, the 2014 meta-analysis by Ciufolini et al., showed that, in 
response to stressful stimuli, patients with Schizophrenia have lower levels than healthy controls. 
Another study looked at healthy controls versus non-psychotic subjects experiencing childhood 
trauma. The cortisol levels were found to be lower in the trauma group than the controls (Carpenter et 
al., 2007). 
In the following study, subject serum samples were assessed for BDNF, β-catenin, and 
cortisol levels. As indicated above, BDNF levels have been found to be lower in both individuals with 
Schizophrenia (Chiou & Huang, 2019; Fernandes et al., 2014) and in ACEs populations. Therefore, a 
greater decrease in BDNF levels in patients with Schizophrenia as their ACEs scores increase is 
anticipated. Comparable results are expected with β-catenin levels as well, as it has been shown to be 
reduced in previous studies utilizing Schizophrenia patients (Cotter et al, 1998). The same results 
have been seen with cortisol levels. Studies have shown attenuated or diminished cortisol levels in 
Schizophrenia and childhood trauma (Ciufolini et al., 2014, Carpenter et al, 2007). In these previous 
studies, the biomarkers and ACEs scores within SSD populations have been demonstrated to 
consistently vary from control levels. Because of this, we will be looking at them specifically within 
only the SSD patient population. We believe we will see variation within the patient population itself 
with regard to biomarker level and ACEs severity.  
 
 











The nature of SSDs is complicated. As discussed in the introduction, though genetic 
associations have been identified, they do not define these disease prodromes. With the long-
lasting impact of ACEs on health, elucidated by the ACE studies in recent years, the intrinsic 
association of disease and environment has become clear. The impact of ACEs and important 
changes to neuronal networking (Boksa 2012), GMV, and neurochemical signaling molecules 
have begun to elucidate the development of SSDs.   
 
SSD  
Schizophrenia is a complex neurodevelopmental disorder. Disorder onset is usually seen 
in early adulthood (late 20’s) and has been associated with dysfunctional synaptic pruning 
(Popovic et al., 2019). There is an established component of heritability, demonstrated by   
. 




twin studies, wherein the rate of heritability is as high as 60–80% (Popovic et al., 2019). There is, 
however, an inextricable environmental component as well. In a study of children with genetic 
risk of Schizophrenia, those adopted into “harmonious” households showed rates of development 
similar to the general population. Those adopted into dysfunctional households had higher rates 
of Schizophrenia (van Winkel et al., 2008). The exposure to ACEs has been demonstrated to be a 
major factor in development of the disease.  
Environmental risk exposure in association with some genetic predisposition is 
hypothesized to be a common process of severe mental illnesses, such as Schizophrenia, Bipolar 
disorder, and Major Depressive Disorder (Davis et al., 2016). The neural diathesis-stress (NDS) 
model, first posited in 1970 by Rosenthal, supposes that trauma mediates pre-existing 
vulnerabilities and triggers the symptoms of Schizophrenia (Walker and Diforio, 1997). Positing 
that cortisol dysregulation affects HPA-axis and leads to downstream dysfunctions in neural 
circuitry, including dysregulation of dopamine (DA) release (van Winkel et al., 2008). Cortisol 
dysregulation has also been an intuitive target for investigation as diseases of hypercortisolism or 
overuse of corticosteroids present with positive symptoms of psychosis.  
Previously the most widely accepted etiology of SSDs was the “Dopamine Hypothesis” 
(DAH). The DAH posited that many of the symptoms presented in Schizophrenia can be 
attributed to the brain's dysregulation of the neurotransmitter DA (Seeman, 1987). DA is an 
excitatory neurotransmitter associated with the limbic system, the reward center of the brain. The 
limbic system has significant connections with the cortex and hippocampus, forming the neural 
bases for reward, decision, and learning associations, respectively. The limbic system is 
extremely influential in the formation of neural pathways. Reward is intrinsically tied to survival, 
such that eating, drinking, and mating, are considered pleasurable and therefore ensure species 
propagation.  




In the DAH excessive DA signaling limbic system is believed to contribute to more 
strongly positive symptoms: hallucinations, delusions, and paranoia. In the cortex a diminished 
expression of DA is considered the probable cause of decreases in cognitive function and 
negative symptoms, such as anhedonia and social withdrawal. DA is the major extrapyramidal 
(substantia nigra, striatum, globus pallidus) neurotransmitter, and this is an important motor area 
related to intentioned motion. This center and its dysregulation have been associated with strange 
or unnatural motion or catatonia sometimes seen in Schizophrenia patients. Increased striatal DA 
release as well as decreasein prefrontal and temporal DA release as a result of receptor 
sensitization (van Winkel et al., 2008), neuronal receptor regulation in response to excess or 
limited neurochemical signaling. This allows cells to upregulate receptors when signals are 
limited and downregulate receptors when signals are too numerous. There is strong evidence in 
support of the complex dopaminergic activity in the instance of psychosis.  
The DAH has prompted investigation of catechol-O-methyltransferase (COMT) as both 
an environmental and genetic instigator of SSDs. COMT is an enzyme that is critical to the 
degradation of DA, making it a natural target of investigation. These studies have come to focus 
on a functional COMT gene valine (Val) to methionine (Met) polymorphism 
(COMTVal158Met). The single nucleotide polymorphism (SNP) actively affects the enzyme’s 
function. In the Met/Val polymorphism enzyme activity is 40% less than in the Val/Val genotype 
(van Winkel et al., 2008). It appears the polymorphism may be neuroprotective. Studies indicated 
correlation of the canonical Val/Val genotype and increased stress-induced paranoia response. In 
a study of 306, 19–24-year-old men, those with the Val allele showed the greatest increases in 
“paranoid ideation and psychoticism”. The Val/Val genotype is also associated with 
hypodopaminergic activity in the Pfc, possibly facilitating stress-induced psychosis response (van 
Winkel et al., 2008). A meta-analysis by Bakker et al., 2008 found neuroprotective effects with 




the Met variant genotypes against tardive dyskinesia in patients with Schizophrenia patients 
(Šagud et al., 2010).  
The DAH has found support with the relative effectiveness of both 1st and 2nd 
generation antipsychotic medicines. These medications all rely on dopamine 2 receptor (D2R) 
antagonism. In 1st generation, or typical antipsychotics, the affinity for D2R is high (Mauri et al., 
2014). While these drugs can be effective, they cause concerning extrapyramidal side effects in 
patients, such as dystonia, uncontrollable muscle contraction, and tardive dyskinesia, repetitive 
involuntary jerking movements of body and face (Seeman, 1987). 2nd generation, or atypical 
antipsychotic, drugs have varying affinity for D2R but are lower than 1st generation Mauri et al., 
2014). Some 2nd generation drugs, such as clozapine, amoxapine, risperidone, and olanzapine, 
act additionally via serotonin (5-HT) as an antagonist at the 5-HT2a receptor (5-HT2aR) (Schmid 
et al., 2014). Interestingly, clozapine not only acts as an antagonist at the 5-HT2aR, but also 
induces internalization of the 5-HT2aR and activates the Akt pathway, which is anti-apoptotic, 
contributing to the considerable efficacy of clozapine and its use in refractory treatment (Schmid 
et al., 2014). 2nd generation drugs have less extrapyramidal effects but have measurably 
increased effect on weight gain, increased risk for diabetes, and some neutropenia (Spertus et al., 
2018, Ingimarsson et al., 2016). Clozapine can cause agranulocytosis and requires careful 
monitoring (Mijovic & MacCabe, 2020).  
With the effectiveness of 2nd generation antipsychotics, it is reasonable to infer that a 
relationship with 5-HT exists in the disease process of Schizophrenia. Interestingly consideration 
of a 5-HT antagonist gained ground from research regarding the function of the psychedelic 
compound LSD on 5-HT2A receptors, notably it induces sustained receptor agonism (Preller et 
al., 2018). In the treatment of Schizoaffective or refractory Schizophrenia the addition of mood 
stabilizers such as lithium, shown to increase Hpc neurogenesis (Neto et al., 2011) and 




anticonvulsants, which modulate both dopaminergic and serotonergic release (Romoli et al., 
2019) indicate that regulation of DA alone is not sufficient (Chen et al., 2007).  
There are GABA system mediated disturbances implicated in the development of 
Schizophrenia. GABA, or Gamma aminobutyric acid, is the brains major inhibitory 
neurotransmitter. In a meta-analysis of 20 genome-wide scans, chromosomal region 5q34 met 
criteria for significant genome wide association (GWA) with Schizophrenia. GABA-Aa6 is an 
isoform of the GABA-A receptor and is located in the same region (van Winkel et al., 2008). 
Glutamic acid decarboxylase (GAD67) is important for cortical interneuron GABA synthesis. 
Decreased expression in GABAergic chandelier interneurons is implicated in disruption of 
cortical activity synchronization and short-term memory in Schizophrenia (Brown, 2011). 
Increased DNA methyltransferase 1 (DNMT1) methylation resulted in decreased expression of 
GAD67 (Brown, 2011). Increased DNMT1methylation activity has also been found in post-
mortem brains of Schizophrenia patients.  
One hundred and forty-five genetic risk SNP loci were outlined in recent genome-wide 
association studies (GWASs) related to Schizophrenia (Popovic et al., 2019). Each of these 
however, demonstrated only weak effect. The studies showed GWAS-based polygenic risk scores 
associated with social and cognitive impairments during early childhood. These were interpreted 
as being possible early manifestations of genetic liability in Schizophrenia. Despite these 
associations, of a little over 8,300 SNPs associated with Schizophrenia, they have been estimated 
to contribute indefinitely to common risk of development (Popovic et al., 2019). This 
corroborates the position that environment has an important modulating aspect to the 
pathophysiology of the disease.  
Explanations, therefore, that incorporate the brain as a system in relation to environment 
and development have begun to replace single agent hypotheses. In this context of brain 




development and environment, ACEs play a major role. Increased hypothalamus-pituitary-
adrenal (HPA) axis activation via stress from ACEs can cause neurobiological dysregulation and 
stress sensitization (Popovic et al., 2019). The effects of overproduction of cortisol and 
subsequent sensitization has been discussed in two pertinent meta-analyses. Patients with 
Schizophrenia have lower stress response cortisol levels than controls, both in anticipation of 
stress and after exposure (Ciufolini et al., in 2014, Zorn et al., 2016). This is indicative of blunted 
cortisol response as a result of sensitization. The systemic hyperstimulation of cortisol promotes 
overproduction of mesolimbic and striatal dopamine (Popovic et al., 2019), leading to 
overstimulation of D2 receptors. In one study, an infusion of 2-Deoxyglucose (2-DG), a non-
metabolizable glucose analog which induces a well-characterized stress response, was 
administered to controls and patients with Schizophrenia. Both groups had appreciable increases 
in cortisol, with no significant difference between them. However, the Schizophrenia patient 
population showed a pronounced increase in DA and norepinephrine release versus controls 
(Ellman et al., 2004, Briere et al., 1993). This study implicates, again, the concomitant 
dysregulation of both HPA/DA systems in the development and symptomatic presentation of 
Schizophrenia and the upstream effect of ACEs. 
 
ACEs   
The idea that the environment affects outcomes is not a new one. However, the ACE 
study drastically modified the landscape of both physical health and mental health outcomes. 
Prior to the ACE study it was more commonly accepted that traumatic childhood experiences 
affected mental health, but whether they also held consequences for physical health was not well 
established. Physical health can be measured with tangible markers, such as HbA1Cs for diabetes. 




The study confirmed long-term physical health could be measurably affected by experiences of 
childhood as well and lent a much-needed objectivity. 
The ACEs Study was undertaken by Drs. Vincent Felitti and Robert Anda. The study was 
expansive and upon completion had surveyed over 17,000 people (about the seating capacity of 
Madison Square Garden). It was executed through Dr. Felitti and Kaiser Permanente’s 
Department of Preventive Medicine in San Diego, CA in collaboration Dr. Anda at the CDC. 
Data from the departments’ Health Appraisal Clinic was collected from volunteers over the age of 
18 from 1992-1998. The study grew from a frustrating pattern observed by Felitti in his weight 
loss clinic. He had a substantial subset of patients that would drop out of the program, only after 
experiencing successful weight reduction. Motivated by this, he began to interview these patients. 
Through these interviews he discovered that a disconcerting number of them had experiences of 
childhood trauma. He eventually connected with Anda, an epidemiologist at the CDC. The 
collaboration that resulted in the execution of the massive study. The results changed the way 
scientific communities looked at the epidemiology of illness. 
 The ACEQ (see Appendix E) assesses eight categories. Those are divided into Subtypes 
of Abuse and Household Dysfunction. Abuse consists of: Psychological, Physical, and Sexual. 
Household Dysfunction: Substance Abuse, Mental Illness, Violence towards Mother, 
Divorce/Separation, and Household Incarceration.  The number endorsed is totaled and the results 
assessed. If any single ACE had been endorsed the likelihood of endorsing another was 87%. The 
results found a staggering 16% of participants endorsed ≥4 ACEs, and 11% ≥5. Women were 
50% more likely to endorse ≥5 ACEs (Felitti & Anda 2009).  
The ACE study laid foundations in social health that would eventually be complemented 
with advances in epigenetic technology. The term epigenetic was coined in 1942 by C.H. 
Waddington, and defines the study of genetic assimilation, alterations made to an already existing 




genetic code. The field gained traction with a 1969 review by Griffith & Mahler and their 
development of the idea that DNA methylation existed as a specific means of modifying the 
functionality of DNA in relation to neuronal adaptation. As research into epigenetics has grown, 
it has become an important facet in the study of both ACEs and mental illness. Life experiences 
are not intangible, they can leave a physical imprint via epigenetic changes on DNA. 
Additionally, these changes are not limited to the immediate health of those they affect. 
Epigenetic changes are potentially heritable and can affect the health of future generations. A 
2019 study by Bruning et al., confirmed one of the major concerns of the ACE study is chronic 
stress. Chronic stress in high ACE households leads to a constant state of heightened sympathetic 
activation, this activity induces epigenetic changes. A large ongoing systematic review of 
epigenetics, ACEs, and mental disorders found methylation of the glucocorticoid receptor NR3C1 
gene was robustly correlated with ACEs (Nöthling et al., 2020). The authors identified effects on 
“neuronal functioning and maintenance, immune and inflammatory processes, chromatin and 
histone modification, and transcription factor binding” (Nöthling et al., 2020). Another recent 
systematic review noted global DNA hypo-methylation in first episode psychosis patients with 
ACEs (Tomassi & Tosato, 2017) as well. Considering approximately one in four children will 
experience some form of trauma before the age of 18 (Klaric & Lovri, 2018), the potential for 
ACEs environmental impact on development and epigenetic change is pronounced.  
Prior to the ACE study in 1998 there was little investigation regarding the scope of 
childhood trauma and its contribution to the health and well-being of an adult individual. There 
was limited scientific literature. This was particularly true in relation to ACEs and those afflicted 
by severe mental illness. Some studies began to surface in the late 1960’s evaluating the effects of 
child abuse. In patients with Schizophrenia, one study found that 32% had experienced early 
childhood physical abuse (Green, 1968). Another study indicated that children in households with 
one parent suffering from Schizophrenia had a 15% probability of developing the illness 




themselves. That probability increased to ≥32% when the illness was present in both parents 
(Tableman, 1981). In a 1987 study by Beck & van der Kolk, 46% of female patients suffering 
from severe intractable psychotic disorder were found to have been the victims of childhood 
incest. Another study in 1991 reported that approximately 43% of chronically psychotic patients 
reported childhood abuse. The abuse was associated with earlier onset of dysfunction, as well as a 
greater incidence of comorbid substance abuse (Goff et al., 1991). 
The potential scope of ACEs in SSD is broad and inextricable. ACEs have a strong 
correlation with the presence of SSDs as well as earlier onset of disease prodrome. One study 
found that a diagnosis of Schizophrenia presented up to 4 years earlier in patients with the 
presence of ACEs (Alverez et al., 2011). In general, women have later onset of symptoms 
(Kocsis-Bogár et al., 2018) without the presence of any ACEs. However, this sex related 
difference is eliminated in the instance of physical abuse, with its presence indicating earlier 
onset in both women and men (Kocsis-Bogár et al., 2018). Another study demonstrated earlier 
age of onset in women alone with the presence of ACEs (Comacchio et al., 2019). Increased 
ACEs are not just associated with earlier onset in women but appear to be predictive for earlier 
onset in women as well (Kocsis-Bogár et al., 2018).  
In a large meta-analysis of patient-control, prospective, and cross-sectional cohort 
studies, across all study types there was significant association of ACEs and psychosis (Varese et 
al., 2012). One study of 50 women with a diagnosis of Schizophrenia demonstrated that 90% of 
the participants had at least one ACE and over 50% had four or more ACEs (Prokopez et al., 
2018). In that study a higher ACEs score also indicated a greater prevalence of persistent auditory 
hallucination (Prokopez et al., 2018). A similar result was found in the previously mentioned 
study by Vallejo et al., 2016. This was a study of 51 men with a diagnosis of Schizophrenia. Of 
them, 94% had at least one ACE, with over 60% scoring four or higher. The study found a greater 
association of the ACE of familial mental illness, as well as the association of increased ACEs 




and the presences of auditory hallucination. In a study of 50 men and 50 women, all diagnosed 
with Schizophrenia, 92% of the participants endorsed at least one ACE and 45% endorsed five or 
more (Propokez et al., 2020). A recent meta-analysis indicated that the total number ACEs was 
strongly associated with the severity of positive symptoms (Bailey et al., 2018) in patients with 
SSDs. An extensive review of ACEs and psychosis (Stanton et al., 2019) demonstrated increased 
ACEs indicated “increased risk of developing psychosis, increased severity of psychotic 
symptoms, increased frequency of affective symptoms and substance use, and worse functional 
impairment” (Stanton et al., 2019). 
There are noted changes in GMV in both ACE and SSD populations. A study on total 
GMV in psychotic patients indicated significant decrease of total GMV in the ACE group 
(Frissen et al., 2018) versus those without ACEs. Reduced Hpc GMV as well as amygdala 
hyperreactivity has been shown in association with ACEs. It predicted worse treatment outcomes 
for those at risk of mental illness (Popovic et al., 2020). Chronic stress, as is often associated with 
ACEs patients, was found to reduce hippocampal dendrites (Magarinos et al., 2011). A functional 
magnetic resonance imaging study showed that ACE exposure resulted in aberrant function of 
parietal areas involved in working memory and of visual cortical areas involved in attention. 
Exposure to any ACEs has been associated with increased activation of left inferior parietal 
lobule, affecting working memory (Quidé et al., 2017). Dorsolateral prefrontal cortex is important 
in working memory and has been shown to exhibit significant reduction in activity during stress 
induction (Qin et al., 2009). In SSDs, decreased GMV in the left dorsolateral prefrontal cortex 
has been associated with exposure to sexual abuse. Patients with Schizophrenia and exposure to 
emotional neglect demonstrated reduction of right dorsolateral prefrontal cortex (Quide et al., 
2017). In another study in patients with Schizophrenia, sexual abuse and physical neglect were 
both negatively associated with functional connectivity of the amygdala and left precuneus during 
emotion processing tasks (Cancel et al. 2017). Results have indicated that with a greater incidence 




of ACEs in SSDs there is increased activation of the posterior cingulate cortex/precuneus and 
dorsomedial prefrontal cortex, as well as reduced activation of the right temporoparietal junction 
(Quidé et al., 2017). The posterior cingulate cortex/precuneus are associated with self-related 
imagery and interpreting image information, dorsomedial prefrontal cortex social cognition, 
temporoparietal junction salience and social context. The functional variations within these areas 
are implicit in the observed social cognitive impairments of SSDs (Quidé et al., 2017). 
 
Review of ACEs Instrument Prevalence 
Adverse childhood experiences have been shown to have cumulative effects on the health 
and well-being of individuals well into adulthood (Felitti & Anda et al., 1998). The continued 
growth and expansion of this developmental research subsequently led to a number of 
instruments designed to measure adverse childhood experiences. Initially the number of studies of 
ACEs was limited as were the tools that scientists and physicians had to assess them. Prior to the 
ACEs study, the most frequently evaluated ACEs were sexual abuse, physical abuse/neglect, 
emotional abuse/neglect. Studies looked at all or one of these in any given population.  
These newer ACEs instruments do not assess a consistent set of traumatic events (Saini et 
al., 2019), as some events are not even broadly designated as trauma, such as domestic chaos or 
parental discord (Roy & Perry 2004). Instruments continue to commonly measure physical, 
emotional, and sexual abuse; but some instruments now quantify additional events such as 
neglect, loss of a parent or parents, exposure to illicit activity by a parent, domestic violence, or 
parental mental illness  (Felitti & Anda et al., 1998). Some instruments also attempt to measure 
severity of events and assess exposure time frames. 
Because of these broad variations ACEs assessment instruments continue to have a lack 
standardization for use within patient populations. There are many studies that attempt to address 




instrument metrics and validity, though there are still no clear guidelines for assessments (Briere, 
1992, Bernstein et al., 2003). The use of many different instruments with widely different 
parameters presents a confounding element to the assessment of childhood trauma when 
correlated with disease incidence. Different parameters may present differences in disease 
association and skew the relationship between trauma and disease presentation. This could result 
in missing critical data in specific population groups. In these instances, an ACE/outcome 
association might exist and fail to be measured due to instrument variation. For example, in 
populations with incidence of a parent with severe mental illness, offspring had a risk that was 
more than double that of the control population (Rasic et al., 2014). Currently there are over 50 
instruments available to assess ACEs with variations in content, criteria, and administration. 
  There are two systematic reviews, Williams et al., 2018 and Matheson et al., 2013, that 
look at the association of psychosis and childhood trauma, both assessing for association of 
childhood trauma and disease presentation. In the 2004 review by Roy & Perry endeavored to 
measure psychometric properties of various instruments and determined that despite the well-
established association between childhood trauma and incidence of psychotic disease, 
consolidation of measurement used would facilitate translation of data across studies. And in 
2018 Saini et al. published a systematic review looking at instrument criteria in general and 
determined that “refined instruments with a focus on capturing abuse events during development 
are warranted in addition to further evaluation of the psychometric properties of these 
instruments”. Because of this variety and scope of instruments, it is important to assess the 
prevalence of instruments used. To our knowledge there are no studies that look at the prevalence 
of instrument use in the assessment of childhood trauma in individuals with psychosis. 
 
 





BDNF is a neurotrophin, a specialized peptide that acts similarly to a neurotransmitter in 
the brain. Neurotrophins require no mechanism to clear or recycle themselves, as is the case with 
neurotransmitters, and are not cytotoxic in excess. Collectively neurotrophins are important in 
neuronal growth, proliferation, and signaling. Of the seven known neurotrophins, four are found 
in humans: neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), nerve growth factor (NGF), and brain 
derived neurotrophic factor (BDNF).    
Neurotrophin receptors, Tropomyosin-related kinase receptors or Trk, are part of the 
receptor tyrosine kinase superfamily. There are 3 Trk receptors: TrkA, B, and C. These receptors 
have a high binding affinity with neurotrophins. Each receptor has subset specificity for a 
particular neurotrophin. TrkA binds NGF and NT-3, TrkB binds NGF, NT-3 and NT-4, and TrkC 
binds NT-3. The Trk receptors have variations in the isoform of their extracellular domains. 
These variations in extracellular domain further regulate which neurotrophins can effectively bind 
the specific receptor.  Because of isoform specificity, each receptor has an associated isoform 
specific neurotrophin. Trk A is isoform specific for NGF and TrkB is isoform specific for BDNF 
(Huang & Reichardt, 2003). 
 
Figure 2. Trk domain and isoform specificity (Roux and Barker, 2002). 




BDNF/TrkB receptor signaling is multifaceted and activates three important cellular 
cascades: phospholipase C (PLC) -γ1, phosphoinositol 3 kinase (PI-3K), and Ras via Son of 
Sevenless (SOS). Both the PLC-γ1 and Ras via SOS cell signaling cascades activate mitogen 
activating protein kinase / extracellular signal-related kinase (MAP/ERK) pathway. This pathway 
works via phosphorylation, which acts like an on/off switch for transcription factors (Orton et al., 
2005). Here it upregulates the activity of transcription factor cAMP Response Element Binding 
protein (CREB) (Fang et al., 2003, Kaplan & Miller, 2000). CREB is an extremely prolific 
transcription factor and is activated by most neurotransmitters signaling cascades. It is 
responsible for the transcription of over 5000 genes including c-fos, BDNF, tyrosine hydroxylase, 
neuropeptides such as somatostatin, enkephalin, VEGF, and corticotropin-releasing hormone 
(operativeneurosurgery.com, Briand et al., 2015). CREB is critical in learning, memory, 
addiction, and mental health. The PI-3K cascade is anti-apoptotic, activating Akt which inhibits 
proapoptotic BCL2 associated agonist of cell death (BAD) and via up regulation of NF-κB 
transcription factor which promotes neuronal cell survival (Middleton et al., 2000) via Bcl-2, anti-
apoptotic molecule.              
 
Figure 3. BDNF/TrkB activation and signal cascade, leading to CREB transcription factor 
activation and upregulation of BDNF and Bcl-2.   




In addition to Trk receptors, neurotrophins may bind and activate receptor p75NTR. This 
receptor is a member of the tumor necrosis factor superfamily of receptors. It was discovered 
during early efforts to identify NGF receptors and because of this association was thought to be 
specific to NGF (Huang & Reichardt, 2001). However, it has since been determined to have an 
equally low binding affinity for all neurotrophins. p75NTR binding can induce apoptosis of some 
cells and support survival of others. In apoptosis, p75NTR activates p53 via the Jun kinase 
cascade. The Jun kinase cascade induces Fas ligand expression and receptor binding and up-
regulates proapoptotic Bax gene. p75NTR promotes survival in only certain cell populations via 
activation NF-κB, promoting neuronal survival in both embryonic sensory and sympathetic 
neurons (Huang & Reichardt, 2001). If any of the Trk receptors and p75NTR are both activated, 
the Trk signaling suppresses the proapoptotic signaling of p75NTR. Interestingly Trk signaling 
does not suppress and appears to work synergistically with the NF-κB/p75NTR signaling 
pathway to support survival (Huang & Reichardt, 2001). The p75NTR signal suppression seems 
to be regulated by the Trk signaling Ras and PI-3K pathways.  
BDNF is a peptide hormone. Transcription generates preproBDNF, which is translated to 
proBDNF and then cleaved to BDNF. Unlike many peptides, both proBDNF and mature BDNF 
are capable of signal activation. BDNF binds with great affinity and specificity to the TrKB 
receptor. ProBDNF, however, binds preferentially to the p75NTR receptor. In embryonal 
development P75NTR acts via the upregulation of the transcription factor NF-κB to support 
embryonal neurons (Huang & Reichardt, 2001). After birth p75NTR functions mainly to 
negatively regulate neurons via apoptosis and inhibition of dendritic arborizations. In the rapidly 
growing and changing brains of children and adolescents, p75NTR acts in tangent with the 
positive neuroplastic regulation of BDNF, supporting the dynamic plastic changes. Until 
adulthood the circulating levels of BDNF and proBDNF are relatively equal (Yang et al., 2014). 
In adulthood, BDNF levels rise and proBDNF decreases significantly. This change in 




concentration is contributed to greater demand for plasticity and neuronal pathway remodeling 
because of rapid and constant growth and restructuring of pathways during development 
(Miranda et al.,). With age, the need for rapid changes in plasticity is moderated and thus the 
proBDNF declines. Increases in proBDNF are seen in pathologic issues of plasticity in diseases 
of advanced age such as Alzheimer’s disease (Miranda et al., 2019).  
BDNF transcription is activated by autocrine stimulation of BDNF binding TrkB 
receptors (Lu, 2003) or via paracrine stimulated activation of CREB transcription factor through 
the activity of excitatory neurotransmitters (Tao et al., 1998). BDNF transcription works on a 
positive feedback loop. The more circulating BDNF, the more activation of BDNF transcription 
and release. Levels of BDNF in serum have been shown to be consistent with levels in 
cerebrospinal fluid, making measurement in serum a reliable indicator of systemic BDNF (Pillai 
et al., 2010, Sahu et al., 2015). Enhancement of BDNF gene expression requires an increase in 
intracellular calcium concentrations necessary for PLC-γ1 signal cascade (Lu, 2003), a common 
signal cascade of most G-protein coupled neurotransmitters. The expression of BDNF mRNA is 
enhanced with glutamate receptor activity and suppressed with GABA-A receptor activation (Lu, 
2003). Cholinergic afferent inputs to the cortex and Hpc also increase the levels of BDNF 
mRNA. D1 receptor activation leads to CREB up-regulation whereas D2 activation is inhibitory 
(Fang et al., 2003). 





Figure 4. Neurotransmitter activation and signal cascade leading to upregulation of CREB 
transcription factor, BDNF, and Bcl-2.  
 
BDNF functions to support various areas of the brain, including the Pfc, the area in 
charge of executive function and decision-making (Chang et al., 2018). It is important in axonal 
guidance and elongation, dendritic collateral branching, and synaptogenesis (Yoshii & 
Constantine 2010, Figurov et al., 1996). The shape and structure of dendritic spines change to 
aggregate and store incoming information over time. Axonal growth allows modification and 
adjustment of nervous system pathways to acclimate to changes in thoughts and behaviors. BDNF 
works on a positive feedback loop, dependent on those actively firing neurons. (Lu, 2003). Active 
neurons respond to excitatory synaptic activity from neurotransmitters or BDNF by rapidly 
inducing BDNF mRNA production as well as cell surface insertion of additional TrkB receptors 
(Lu et al. 2003). In the neocortex, BDNF is critical to dendritic arborization of pyramidal neurons 
and circuitry and signal modulation (Huang & Reichardt, 2001, Escobar et al. 2003). BDNF 
supports plasticity via LTP in the insular cortex (Escobar et al. 2003). In both the somatosensory 
and visual cortices activity induced expression of BDNF was decreased with signal deprivation. 




In studies of Xenopus retinal ganglion, exogenous BDNF led to increased complexity of axonal 
branching and dendritic arborization (Lom & Cohen, 1999). BDNF is implicated in the formation 
of ocular dominance columns via sorting effects on thalamic afferents (Huang & Reichardt, 
2001). Increased BDNF levels enhance maturation of interneurons. BDNF mediates the critical 
period of visual development via thalamic afferent sorting and excitation of pyramidal neurons 
from visual stimuli (Huang & Reichardt, 2001).     
BDNF plays a key role in the Hpc. It maintains neuroplasticity and mediates 
neurogenesis throughout the brain in childhood and adolescence. Continued neurogenesis occurs 
only in the Hpc throughout adulthood as well (Stanton et al., 2020) and has continued support via 
BDNF activity. It functions to maintain neuroplasticity in the Hpc by acting as a signal protein for 
axonal guidance as well as assisting in conversion of early LTP to late LTP (Purves et al, 2001).  
Because BDNF has a slower rate of transcription than c-fos, another CREB protein associated 
with early LTP, it is considered critical for the transition of acute to late LTP which is critical for 
long-term memory formation in the Hpc (Lu, 2003). BDNF is expressed in pyramidal neurons of 
Hpc layers CA1 and CA3. TrkB is expressed more ubiquitously throughout the Hpc: CA1 and 
CA3 pyramidal cells, dentate granule cells, and inhibitory interneurons (Huang & Reichardt, 
2001). Very few p75NTR receptors exist here, and therefore exhibit little influence on signaling. 
The BDNF/TrkB signaling in the Hpc is believed to support LTP via modulating the presynaptic 
nerve terminal effectiveness. BDNF generates repeated exocytotic signals to enhance the 
effectiveness of presynaptic signals reaching postsynaptic neurons. BDNF also enhances 
presynaptic vesicle release, promoting vesicle docking at presynaptic membrane (Huang & 
Reichardt, 2001).   
Because BDNF is associated with neurogenesis and dendritic remodeling, it has been a 
target of interest for stress and trauma-related changes in neuronal function and physiology as 
well as psychological disorders (Theleritis et al., 2014) where levels have been shown to be 




decreased. There is existing support for dose-response relationship in ACEs exposure and BDNF 
levels, with greater exposure demonstrating lower levels in patients with psychoses (Aas et al., 
2013). Cortisol, the body’s major stress hormone, reduces BDNF mRNA levels in the Hpc. 
Patients with low plasma BDNF levels who have a history of ACEs can indicate more 
progressive illness (Aas et al., 2019).  Both acute and chronic stress demonstrate decreased 
BDNF levels in the Hpc in animal models (Neto et al., 2011). Exogenous glucocorticoids also 
reduce Hpc BDNF levels (Neto et al., 2011).   
 BDNF levels have been shown to be decreased in patients with Schizophrenia 
(Fernandes et al., 2015, Stanton et al., 2020). There is evidence that BDNF expression increases 
with the administration of antipsychotic medications, particularly atypical antipsychotics 
(Gonzales-Pinto et al., 2010). D1 receptor activation leads to CREB/BDNF up-regulation but D2 
activation inhibits BDNF expression (Fang et al., 2003). Because both typical and atypical 
antipsychotics act predominantly as D2 receptors antagonists (Mauri et al., 2014), this may be 
why we see increases in BDNF levels in medicated vs drug-naïve patients with SSD. The plasma 
levels of BDNF in 18 first episode psychosis drug naive subjects were found to be decreased 
versus controls. Following antipsychotic treatment with olanzapine, the BDNF plasma 
concentration increased toward control levels (González-Pinto et al., 2010). The antagonism of 5-
HT2A by ketanserin, a quinazoline derivative 5-HT antagonist sometimes used as an anti-
hypertensive, partially blocks the effect of stress on BDNF expression (Neto et al., 2011). This 5-
HT2AR antagonism again contributes to the effectiveness of atypical antipsychotics such as 
clozapine and olanzapine but may also be a relevant mechanism in the approximation towards 
normal BDNF levels in treated patients. However, meta-analyses indicate that, despite the 
measured increase in BDNF in patients with Schizophrenia on anti-psychotics, their levels remain 
statistically lower than controls (Green et al., 2011).   




BDNF has an important polymorphism associated with both ACEs and SSD, it is BDNF 
Val66Met. It is a SNP replacement of a valine (Val) with a methionine (Met) at position 66. The 
Met variants, Met/Met and Val/Met, are strongly associated with decreased neuronal BDNF 
levels. They show greater incidence of stress-induced paranoia than Val/Val carriers (van Winkel 
et al., 2008). MRI’s have shown Met carriers to have decreased hippocampal volumes with 
comorbid ACEs. ACEs have demonstrated an additive effect on volume loss in the hippocampal 
subregions CA4/dentate gyrus and CA2/3 with the presence of the Met allele in Schizophrenia 
(Popovic et al., 2019). The Met allele is also associated with significant executive function 
impairments of cognition, working memory, and attention (Stanton et al., 2019). In a study of 249 
patients with SSD with increased ACEs, those with a Met variant displayed worse cognitive 
dysfunction than monozygotic Val carriers (Popovic et al., 2019).   
BDNF has been considered a potential biomarker for Schizophrenia because of its 
consistently lower levels in SSDs (Stanton et al., 2020). BDNF is vital in mental health and 
decreases or variation in BDNF levels are seen not only SSDs but also in MDD, BP I and II, and 
neurocognitive disease such as Alzheimer’s disease and Parkinson’s. Because of this it has been 
difficult to establish it as a diagnostic biomarker for SSDs, despites its strong association 
(Cattaneo et al., 2016). There is, however, potential for it to be effectively used as a biomarker for 
treatment efficacy in patients with SSD as demonstrated Zhang et al. 2018. This study measured 
plasma BDNF in patients with Schizophrenia. They were started on olanzapine, administered 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and BDNF levels 
were assessed over a 12-week course. The study found a significant positive correlation between 
increase in plasma BDNF and improvement in the RBANS total scores. They found significant 
correlation of BDNF increase and RBANS attention sub-score improvement in (Zhang et al., 
2018). In this context, BDNF levels could be utilized similarly to certain cancer markers to assess 
patient progress and monitor treatment.   




β-catenin   
β-catenin is a highly conserved protein most commonly associated with the canonical 
Wingless-type mammary tumor virus integration site (Wnt) signaling pathway during embryonic 
development (Medina et al., 2018). It serves two primary functions in adult physiology: cell 
adhesion and as a genetic transcription factor. It has since emerged as a critical neurotrophic 
factor (Zhang et al., 2018). β-catenin has been shown to function in regulating neuronal 
development and differentiation of nerve cells (Teo et al., 2018), and dendritic morphogenesis 
and axonal guidance (Zhang et al., 2018). It also functions in synaptic stabilization and 
neuroplasticity in the formation and maintenance of memory within the Hpc (Teo et al., 2018).  
β-catenin is ubiquitously expressed throughout the body, including the brain. Animal 
studies have indicated expression is greatest in neurons during development, with an initial 
decline and plateaus throughout adulthood. In advanced age, β-catenin levels show increases (Teo 
et al., 2018). Levels during development are critical. Under expression may cause decrease in 
progenitor cells with premature differentiation of cells. Overexpression can cause the opposite, 
decreased differentiation and excessive neuronal outgrowth (Teo et al., 2018).  
Wnt3a, a prototypic Wnt ligand, binds an NMDA receptor and activates the Wnt/β-
catenin pathway, with stimulation of Wnt expression and rapid secretion. When the Wnt/β-
catenin pathway is inactive, β-catenin is phosphorylated and marked for proteasome 
ubiquitination via glycogen synthase kinase 3 β (GSK3β). There are both canonical and non-
canonical signaling pathways activated by the secreted Wnt. The canonical pathway is the Wnt/β-
catenin pathway. Wnt ligand binds Frizzled (Fzd) and LRP5/6 co-receptors. This activates 
Dishevelled (Dvl). Dvl inactivates GSK3β, which inhibits the phosphorylation and ubiquination 
of β-catenin.  This allows β-catenin to saturate the cytoplasm, which results in nuclear 




translocation of β-catenin. In the nucleus, it acts as co-activator with TCF/LEF1, as a 
multifunctional transcription factor for target genes (Zhang et al., 2018, Teo et al., 2018).  
  
Figure 5. Overview of Wnt canonical and non-canonical signaling pathways.  
(Garcia et al., 2018) 
 β-catenin supports synaptic stability by acting as an adhesion protein in cytoskeletal 
composition. It acts as an anchor for E-cadherin, which links to the actin cytoskeleton in Hpc, 
hypothalamus, and amygdala (Teo et al., 2018). β-catenin has also been shown to have important 
maintenance function in dendritic arborization as a cytoskeletal element within the Hpc 
supporting synaptogenesis (Yu & Malenka 2003). Cadherin-complexes are regulated during 
synapse formation and remodeling by redistribution of β-catenin to active spines (Chen et al., 
2006).   
The Wnt/β-catenin pathway modulates BDNF expression. Activity-dependent Wnt 
secretion acts as paracrine stimulation of BDNF transcription in nearby cells, as well as activated 
neurons, contributing to the potentiation of neural circuits (Zhang et al., 2018). In a study of 
cortical cultures, Wnt3a induced both β-catenin and concomitant BDNF up-regulation (Zhang et 




al., 2018). In vivo studies with intrathecal Wnt3a injection resulting in significantly increased 
BDNF expression following administration. β-catenin is likely to directly target BDNF 
expression because β-catenin's’ promoter contains the binding motif for BDNF’s co-activators, 
TCF/LEF1. Considering the common functions as both neurotrophic and cytoskeletal agents, 
their co-activation could be particularly important in diseases like schizophrenia, in which 
decreased or modulated expression of both proteins is indicated. Sutton et al., 2007 found that 
both haloperidol and clozapine up-regulated the expression of Wnt pathway molecules including 
β-catenin. This could be a modulating factor in the increase in BDNF expression seen in treated 
patients.  
Studies on the expression or presence of β-catenin in relation to Schizophrenia have 
consisted of gene mapping and expression (Pedrosa et al, 2010), as well as protein expression in 
particular brain areas (Park et al, 2011). As early as 1998, Cotter et al. found a decrease in the 
concentration and distribution of β-catenin in Hpc of postmortem Schizophrenia patients. One 
study found significantly increased Wnt-1 expression in the CA3 area of the Hpc pyramidal cells 
in post-mortem patients with Schizophrenia (Miyaoka et al., 1999) vs controls.  
 In the dorsolateral prefrontal cortex of post-mortem schizophrenia patients, another study 
found reduced levels of the GSK3β (Kozlovsky et al., 2004). This is interesting given the effects 
of chronic stress and cortisol on GSK3β and β-catenin. Stress has been shown to modulate 
GSK3β activity and subsequent β-catenin expression (Garza et al., 2012). An animal study using 
dexamethasone to induce the physiologic state consistent with chronic stress found decreased 
phosphorylation of GSK3β and subsequent increased GSK3β activity and decreased levels of β-
catenin (Garza et al., 2012) in the Hpc. A study of chronic stress induced by repeated forced swim 
tests resulted in a reduction of phosphorylated GSK3β, rendering it active with increased overall 
levels of GSK3β and decreased β-catenin in Pfc and dorsal Hpc (Teo et al., 2018). Another 
clinical study found a positive correlation of GSK3β and negative symptoms in psychosis 




(Bouseman et al., 2013). Chronic stress upregulates activated GSK3β, and the subsequent 
increased negative symptoms, and decreases β-catenin. It is possible following a time with 
sensitization of cortisol, there is similar sensitization with GSK3β, seen in post-mortem 
Schizophrenia patients.  
Wnt/β-catenin signaling is modulated by a family of secreted glycoproteins Dickkopf 
(Dkk) 1-4. These suppress Wnt signaling and are crucial for embryonic development (Ftouh et 
al., 2005). In adults they are involved in apoptosis and synaptic regulation (Ftouh et al., 2005). 
Dkk-1 promotes endocytosis of the LRP5/6 co-receptor, preventing β-catenin translocation, 
which results in neuronal apoptosis and dendritic atrophy (Teo et al., 2018). Elevated stress has 
been shown to induce elevated levels of Dkk-1 in mice. In patients with Schizophrenia 
significantly higher levels of Dkk-1 were found (Al-Dujaili et al., 2020).  Dkk-3 is densely 
expressed in the superior temporal cortex. In patients with schizophrenia, Dkk-3 expression was 
significantly decreased (Ftouh et al., 2005). There is definite reason to continue to build 
understanding of the association of β-catenin and SSD.  
  
Cortisol   
Glucocorticoids are important hormones necessary to maintain homeostasis in times of 
biological insult. Cortisol is the active glucocorticoid in humans. It regulates metabolism, 
modulates inflammation and immune function, and mediates response to stress (Thau & Sharma, 
2020). There are glucocorticoid receptors (GR) ubiquitously throughout the body. They affect 
most organ systems including metabolic, immune, and nervous. Cortisol will bind 
mineralocorticoid receptors (MR), but with lesser affinity. MR are not ubiquitous and therefore 
much more tissue specific.   




Cortisol is a steroid hormone, synthesized from cholesterol. Cortisol release is regulated 
via a negative feedback mechanism at various levels of expression via GR in the PVN or in the 
adrenal gland.  Expression of cortisol is elicited in response to stress stimuli. Excitatory signaling 
is sent via the nucleus of the solitary tract (NTS) of the sympathetic nervous system (SNS). The 
SNS signals the hypothalamus at the paraventricular nucleus (PVN) to release corticotropin 
releasing hormone (CRH) in response to a stress stimulus. CRH acts on the anterior pituitary 
which releases adrenocorticotropic hormone (ACTH). ACTH stimulates adrenal cortical cortical 
zona fasciculata cells and the release glucocorticoids, primarily cortisol. Only a small percent of 
cortisol circulates freely in the blood, approximately 4%. The rest is bound to corticosteroid-
binding globulin (CBG) or albumin (Ramamoorthy & Cidlowsky,  2016). In the absence of 
stimuli, the HPA-axis is regulated by circadian rhythm, resulting in higher cortisol levels in the 
morning at waking and lower levels at night (Ramamoorthy & Cidlowski, 2016). 
   GR are intracellular and bound to chaperone proteins in the cytoplasm (Kadmiel & 
Cidlowski, 2013). When cortisol binds the GR, it undergoes a conformational change and 
translocates to the nucleus where it functions to suppress or enhance transcription. Cortisol 
functions this way to ensure availability of resources in the event of a challenge and suppressing 
unnecessary protein production. Transcriptional modulation of cortisol signaling is mediated via 
diverse receptor isoforms resulting from alternative splicing and alternative translation initiation. 
Transcriptional and translational isoforms of GRs are widespread allowing for refinement of GR 
signaling in a given cell or a tissue type (Kadmiel & Cidlowski, 2013). Cortisol transcriptional 
variation is also modifiable via the GRE unit upon translocation of the cortisol/GR unit (Kadmiel 
& Cidlowski, 2013). GREs are imperfect palindromic sequences of DNA containing two 
hexameric half sites separated by three base pairs (Kadmiel & Cidlowski, 2013). GREs provide 
additional signal modifications. These modifications allow increased selective regulation of both 
suppression and enhancement of gene expression.   




In the immune system, cortisol is critical in mediating ant-inflammatory responses and 
acts on most cells of the immune system (Kadmiel & Cidlowski, 2013). It inhibits dendritic cell 
maturation, mediates migration and apoptosis. It has been shown to enhance phagocytosis of 
polymorphonuclear leukocytes (PMNs) by macrophages, thereby decreasing their inflammatory 
activity. It inhibits PMN migration by decreasing cell adhesion molecule expression (Kadmiel & 
Cidlowski, 2013) but also appears to inhibit PMN apoptosis. Cortisol induces apoptosis of 
inflammatory T cells, while enhancing survival of T regulatory cells. In B cells it can cause 
decreased mature cell numbers and increased number of progenitor cells. It decreases B cell 
levels of Bcl-2 anti-apoptotic protein, and subsequently increases B cell apoptosis. Cortisol is 
important in the management of metabolism and glucose availability, ensuring adequate 
availability for the brain. It acts on the liver, pancreas, adipose and muscle. Increased levels in the 
liver lead to decreased glycogen synthesis and increased gluconeogenesis.  In the pancreas, 
cortisol increases glucagon expression and decreases the expression of insulin. (Thau & Sharma, 
2020)  
Cortisol activity in the nervous system is most important in response to stress via the 
HPA-axis. Cortisol is released in response to stress stimuli, which can be an actual threat or an 
anticipated threat or stress event. Cortisol enhances the expression of glucagon, epinephrine, and 
other catecholamines. GRs in the forebrain regulate HPA axis and behavior under stress. GRs in 
the amygdala play an important role in memory acquisition and fear conditioning (Kadmiel & 
Cidlowski, 2013). In a state of acute stress, the body will upregulate cortisol expression. The 
body does this with the intention of fueling catabolic processes to provide itself with energy via 
regulation of glucose in the liver and pancreas to support the fight or flight response to stress. In 
abbreviated instances of acute stress, this system functions well to mitigate the stress event. 
Levels will return to normal through feedback inhibition of the HPA-axis, Pfc, and Hpc (Lee et 
al., 2015).  




In the Hpc, GR are most densely expressed in the dentate gyrus, though they are 
expressed throughout CA1-4 as well. As mentioned, the Hpc and Pfc are important areas in 
feedback regulation of cortisol. In the instance of chronic stress and the stress signaling is not 
abated, circulating cortisol remains elevated. This continued elevation eventually results in 
damage to both hippocampal and cortical neurons (Lee et al., 2015). This affects the brain’s 
ability to regulate cortisol via the inhibitory feedback mechanism. GR density has been shown to 
be markedly decrease in the Hpc dentate gyrus, CA1, CA3, and CA4 of Schizophrenia patients 
versus controls (Webster et al., 2002). The same study also demonstrated decreases in GR in both 
Pfc and inferior temporal cortex (Webster et al., 2002). Receptor trafficking is a common method 
to manage signaling when an overabundance of a signal molecule is present to prevent 
excitotoxicity. These marked decreases in GR may be representative of actual cell loss as GMV 
loss is seen in SSD in these areas (Webster et al., 2002). In animal studies with induced chronic 
stress or repeated glucocorticoid administration, results show degeneration of Hpc neurons, with 
dendritic atrophy and decreased cell size (Popovic et al., 2020). This cortisol induced 
neurotoxicity can lead to impaired or decreased myelination. Cortisol induced neurotoxicity can 
also affect signaling related to calcium channels caused by pathologic increase in intracellular 
calcium concentrations (Damsted et al., 2011).  Animal studies have shown that high doses of 
methylprednisolone or dexamethasone increase apoptosis in the PVN. The high dose GR 
activation in the PVN significantly inhibits Akt/CREB activation, which in turn reduced 
expression of anti-apoptotic Bcl-2 and BDNF, and increasing pro-apoptotic Bax gene expression 
and activating pro-apoptotic BAD signaling cascade leading to increased cell apoptosis (Zhang et 
al., 2020)  
Higher cortisol activity levels seen in SSD have been associated with higher incidence of 
positive symptoms. This is suggestive of dysregulation of information coding, inhibiting patients 
with SSDs from discriminating between actual and irrelevant threats (Webster et al., 2002). As 




mentioned previously, patients with Schizophrenia and/or ACEs have blunted cortisol levels in 
response to stress events versus controls (Ciufolini et al., in 2014, Zorn et al., 2016). A study of 
non-medicated first episode psychosis also indicated a blunted cortisol response (Popovic et al., 
2020), indicating that antipsychotic medications are not mediating this response. This supports 
that cortisol expression itself is not mediated by antipsychotics. This differs from what has been 
seen with both BDNF and β-catenin levels and the use of antipsychotics, which appears to 
modulate levels. 
 











Institutional Review Board (IRB) 
Human Subjects Protocols and Interventions IRB #2020021 Approved 6/29/2020.  
IRB protocol was followed for all collection and handling of venous blood samples for this study. 
See Appendices A, B, C, D, E, & F for all supplemental IRB materials. 
 
Patient Selection  
Participants were screened via onsite nursing staff to facilitate ease in assessing criteria for 
inclusion. Following positive recruitment assessment by nursing staff and willingness to 
participate, subjects were introduced to the research staff. All patients were required to be current 
on their medications to control for the potential of antipsychotics to modulate BDNF levels. 
Because the patients were recruited from an injection clinic, not only were they current but they  




were all administered their injections on the day of recruitment, allowing for greater 
standardization of antipsychotic affect. 
• Patient may qualify if they meet the following criteria:  
o Between the ages of 18-64 
o Current diagnosis and treatment of schizophrenia, schizophreniform disorder or 
schizoaffective disorder 
o Has completed at least 8 years of formal education 
o Speaks and reads English fluently 
o Does not have a proxy for medical decision-making, legal guardian, or been 
otherwise determined unable to give consent 
o Is current and compliant on antipsychotic medications 
o IQ >70 or no previous diagnosis of intellectual disability 
o No past diagnosis or suspected current diagnosis of a neurodevelopmental 
disorder (e.g., autism, learning disability) or neurocognitive disorder (e.g., 
dementia) 
o No history of major head trauma (defined as loss of consciousness for 30 minutes 
or longer) or brain surgery (Note: History of concussion, including brief loss of 
consciousness, is okay)  
o No history of psychosis secondary to a medical condition or diagnosis of 
psychosis secondary to substance abuse 
o No history of presence of endocrine conditions that would alter prolactin or 
cortisol levels, such as Prolactinoma or Cushings’ respectively 
o If female, is not pregnant or lactating 
Following assessment for inclusion criteria, all participants were administered informed consent 
forms, participant data sheet, ACEQ, and SCID-5-CV. Upon completion of all paperwork and 
assessments, participants were subject to collection of 8mL of blood in commercial red topped 
vacutainer tubes from Becton Dickinson (BD). Blood samples were collected on site at Family & 
Children’s Services (FCS) by an FCS LPN/RN. Samples were spun down to separate clotted 
blood from serum on site by Primary Investigator (PI), Rebecca Gaglia. 









The ACEQ is a self-reported instrument to assess Adverse Childhood Experiences designed by 
Filetti, et al 1998. One point is given for each affirmative answer to the assessment questions. The 
number endorsed per patient was totaled and the results assessed.  
Adverse Childhood Experience (ACE) Questionnaire 
Finding your ACE Score While you were growing up, during your first 18 years of life: 
1. Did a parent or other adult in the household often …Swear at you, insult you, put you 
down, or humiliate you? Or Act in a way that made you afraid that you might be 
physically hurt? 
2. Did a parent or other adult in the household often …Push, grab, slap, or throw 
something at you? Or Ever hit you so hard that you had marks or were injured? 
3. Did an adult or person at least 5 years older than you ever…Touch or fondle you or 
have you touch their body in a sexual way? Or Try to or actually have oral, anal, or 
vaginal sex with you? 
4. Did you often feel that …No one in your family loved you or thought you were 
important or special? Or Your family didn’t look out for each other, feel close to each 
other, or support each other? 
5. Did you often feel that …You didn’t have enough to eat, had to wear dirty clothes, and 
had no one to protect you? Or Your parents were too drunk or high to take care of you or 
take you to the doctor if you needed it? 
6. Were your parents ever separated or divorced? 
7. Was your mother or stepmother: Often pushed, grabbed, slapped, or had something 
thrown at her? Or Sometimes or often kicked, bitten, hit with a fist, or hit with something 
hard? Or Ever repeatedly hit over at least a few minutes or threatened with a gun or 
knife? 
8. Did you live with anyone who was a problem drinker or alcoholic or who used street 
drugs? 
9. Was a household member depressed or mentally ill or did a household member attempt 
suicide? 
10. Did a household member go to prison? 
See also Appendix E.  
 




Structured Clinical Interview for DSM-5 - Clinician’s Version  
The Structured Clinical Interview for DSM-5, Clinician Version (SCID-5-CV), is a structured 
interview for making DSM-5 diagnoses. Research PI, Rebecca Gaglia administered all SCID 
interviews for consistency. SCID results were reviewed with advisor following completion. The 
use of the SCID allows for consistency in diagnostic procedure as well as assessment of Use 
Disorder (UD), which has a strong association with SSDs. It takes care to attempt to confirm 
onset of disease prodrome in the context of illness, substance use, and changes or discontinuation 
of medication. 
See Appendix F.  
 
Blood Draw Procedure 
Blood samples were obtained from participants. Following standard sanitary blood draw 
procedures, 8.0mL blood was drawn from an antecubital vein. Red topped Becton Dickinson 
(BD) Vacutainer tubes were used for all samples. Samples were transported by PI from FCS to 
OSU-CHS for processing and long-term refrigerated storage, according to the established 
protocols of the OSU-CHS Biohazard Biosafety committee. 
 
Biological Sample Storage and Processing 
Blood was allowed to clot, undisturbed, at room temperature for 15–30 minutes. Blood was then 
chilled 10-20 minutes. The sample was centrifuged at 1,600 x g for 10 minutes to separate serum 
supernatant from clot. Following centrifugation, the serum was chilled at 2–8°C until transfer to 
lab for storage. Blood samples were transported from FCS to the OSU-CHS (E-367) by PI, 




Rebecca Gaglia, following the established protocols of the OSU-CHS Biohazard Biosafety 
committee. The samples were maintained at 2–8°C during handling. Serum not analyzed 
immediately was apportioned into 1 mL aliquots and stored at –20°C. Additional aliquots of 3 
sets of 200 microliters were made and stored at –20°C. Repeated freeze-thaw cycles were 
avoided. All ELISAs were processed from secondary aliquots with no samples thawed more than 
three times. 
 
BDNF ELISA  
Thermo Scientific Pierce Human BDNF ELISA Kit (EH42RB) was used to measure serum 
sample BDNF levels. Standards were run in duplicate and patient serum samples run in 
septuplicate. All samples were read immediately at 450nm and 550nm. Values at 550nm were 
subtracted from those at 450nm to correct for optical imperfection. A standard curve was 
generated from the mean of standards, line of best fit determined by regression analysis using a 
four-parameter (IC50, x-intercept, y-intercept, and slope) logistic curve-fit.  Sample concentration 
was determined with standard curve and then multiplying value times sample dilution factor, 
1:200. 
See Appendix G. 
 
 β-catenin ELISA  
MyBiosource Human β-catenin (CTNNβ) ELISA Kit (MBS724736) was used to measure serum 
sample β-catenin levels. Standards were run in duplicate and patient serum samples were run in 
sextuplicate, except A2 which had limited serum and was run quintuplicate. All samples were 
read immediately at 450nm. Optical Density (OD) values are subtracted by the mean of the blank 




control wells prior to result interpretation. A standard curve was generated from the mean of 
standard, line of best fit determined by regression analysis using a four-parameter logistic curve-
fit.  Sample concentration was determined by the standard curve. 
See Appendix H. 
 
Cortisol ELISA  
Thermo Fisher Scientific Human Competitive ELISA Kit (EIAHCOR) was used to measure 
serum sample cortisol levels. Standards were run in duplicate and patient serum samples run in 
septuplicate. All samples were read immediately at 450nm. All Optical Density (OD) values are 
subtracted by the mean of the blank control wells prior to result interpretation. Standard curve 
was generated from the mean of standard, line of best fit determined by regression analysis using 
four parameter logistic curve-fit.  Sample concentration was determined by the standard curve. 
See Appendix I. 
 
Methodology for Systematic Review  
The study searched Embase and SCOPUS, using six sets of search terms: adverse child 
experience psychosis (ACE P), adverse child experience Schizophrenia (ACE S), adverse child 
experience Schizoaffective (ACE Sa), childhood trauma psychosis (CT P), childhood trauma 
Schizophrenia (CT S), childhood trauma Schizoaffective (CT Sa).   
The articles were compiled separately in duplicate to account for bias and reproducibility. Studies 
were pulled into Paperpile, a web-based reference management software program. They were 
sorted via exclusion/inclusion criteria as follows. Exclusion criteria were: 1) Outside of the date 




range of January 2000 to May 2019, 2) Study does not assess childhood trauma, and 3) Study that 
does not include psychosis, Schizophrenia or Schizoaffective disorder.  
Exclusions included reviews, commentary, and meta-analysis, poster/conference abstracts, and 
studies that do not have a definitive trauma assessment instrument. Detailed criteria are outlined 
in the supplement. Two independent reviewers (RJG and AS) reviewed studies and evaluated the 
titles and abstracts of all articles identified by the search strategies. The full articles of those 
remaining were assessed for the instrument used. The instruments isolated from the search were 
evaluated to ascertain the categories of trauma included and the instruments’ prevalence of use. 
The PRISMA-P (Shamseer et al., 2015) was followed for this systematic review. Upon 
completion of exclusion criteria, remaining studies were sorted into subcategories based on the 
instrument utilized in the study to assess childhood trauma. These instruments were then 
quantified by prevalence of use. 
See Appendix J.









This study looked specifically within an SSD patient population to assess variation of 
biomakers within the population with respect to severity of ACEs scores. The exclusion of 
controls was adopted given existing evidence that there are already demostrable differences in 
SSD populations and controls. Therefore, the investigation was focused on effect within the 
disease population. The data collected from them was assessed and including population 
demographic and Use Disorder associations as well as the variation of biomarker levels in 
relation to the ACEs score severity. 
The systematic review of instrument prevalence found an unexpected predominance of 
one study, the CTQ, with more evenly distributed use among most other.  
 
Patient Demographic Analysis 
Subjects were recruited from FCS, an outpatient Community Mental Health Center. The 
patient sample consisted of 11 patients (4 Female, 7 Male) with diagnoses of either Schizophrenia 
(Sz) or Schizoaffective (SzA), (Sz=2M), (SzA=4F, 5M). All subjects were administered the 
SCID-5-CV to confirm diagnoses, the ACEQ, and a blood draw to evaluate serum for 
biomarkers. Demographic information is illustrated in Table 1. Five of eleven participants lived 




with a non-spouse family member, two with a spouse, and the remaining four lived by 
themselves or with a non-relative roommate. All had achieved a GED/Diploma or higher. 63.6% 
including, all four of the female participants, were Caucasian. The seven men offered a more 
diverse sample with some overlap in ethnicity: 42.9% Caucasian, 42.9% African American, and 
28.6% Native American. 36% endorsed earning $10,000-$35,000, putting them at or within 200% 
of the Federal Poverty Level (FPL) for households of 1-3. The remaining 64% endorsed $0-


















Table 1. Demographic information of study sample  (n=11) 
Mean Age years, SD 33.36 (9.12) 
% Female 36.4 
Ethnicity % (May Overlap)  
  African American 27.3 
  Native American 18.2 
  Caucasian 63.6 
  Native Hawaiian or Other Pacific Islander 0 
  Asian 0 
  Hispanic 0 
Education %  
  High School / GED 54.5 
  Some Undergraduate Education 27.3 
  Trade Degree / Certification 9.1 
  Associate degree 9.1 
  Bachelor’s Degree 0 
  Some Graduate Education 0 
  Graduate / Professional Degree 0 
Military % 0 
Marital Status %  
  Single 54.5 
  Married 18.2 
  Separated 0 
  Divorced 27.3 
  Widowed 0 
Occupation Status %  
  Unemployed / Disability 54.5 
  Employed PT 9.1 
  Employed FT 27.3 
  Student FT 9.1 
  Student PT 0 
Annual Income %  
  $0 - $10,000 63.6 
  $10,000 - $35,000 36.4 
  $35,000 - $60,000 0 
  $60,000 - $85,000 0 
  $85,000 - Above 0 
Insurance %  
  No Insurance 54.5 
  Medicaid 27.3 
  Medicare 9.1 
  Private Insurance 9.1 










SCID-5-CV for Mood Disorders, Schizophrenia, and Use Disorder was performed on 
each participant. The SCID is extremely valuable in research involving mental illness. Though 
most psychiatric intake assessments are based on the criteria of the DSM-5, the SCID is formatted 
directly from it and ensures consistency in diagnosis. Of the patients that opted to participate, 
seven were diagnosed as SzA BP (Schizoaffective Bipolar Disorder), two with SzA D 
(Schizoaffective Depressive Disorder), and two with Sz (Schizophrenia). All patients endorsed 
delusions, hallucinations, and negative symptoms in the form of avolition. Only four 
demonstrated disorganized speech. None of the participants demonstrated disorganized behavior. 
Three of those four with disorganized speech, however, did endorse a UD. 
Patient 
SCID Dx 







SzA BP Mi-A ✓ ✓   ✓ 
SzA D X ✓ ✓   ✓ 
SzA BP X ✓ ✓ ✓  ✓ 
Sz Sv-C ✓ ✓   ✓ 
SzA BP Sv-A, Mo-C ✓ ✓   ✓ 
SzA BP Mi-A ✓ ✓ ✓  ✓ 
SzA D X ✓ ✓   ✓ 
SzA BP X ✓ ✓   ✓ 
Sz Mo-A ✓ ✓   ✓ 
SzA BP Mo-C ✓ ✓ ✓  ✓ 
SzA BP Mo-C, Sv-M ✓ ✓ ✓  ✓  
Table 2. SSD, UD Diagnoses and Positive and Negative Symptom Endorsement 
 
Use Disorder (UD) was assessed in all participants. UD diagnosis is assessed based on 
use of a substance over a 12-month period of time. This includes use that has stopped at present 
but was active within the last 6 months. The SCID assesses for an exhaustive of list substances, 
except Nicotine, but in this population only these were endorsed: Alcohol (A), Cannabis (C), or 
Methamphetamine (M). It can be characterized as Mild (Mi), Moderate (Mo), or Severe (Sv).  




Seven of the eleven, or 64% of participants, endorsed varying degrees of UD. The most common 
was cannabis, in four of the seven (57%) followed by alcohol with three (43%), and only one 
endorsing methamphetamine use (14%). Two of those seven had two concomitant UDs (29%), 
and none had more than two.  
 
ACEQ 
Table 2 summarizes the total number of ACEs endorsed per patient from the ACEQ. The 
mean number of ACEs was 4.18 (±2.23 SD). The most commonly endorsed ACE was parental 
separation or divorce, with nine of eleven, (82%) of patients endorsing. The second most 
common, endorsed by eight of eleven, (73%) of patients, was a problem drinker/alcoholic or use 
of street drugs in the home. Two of the four female patients endorsed the sexual abuse, none of 




           Total / 
ACEQ 
1.     1        1  1    1  1  4 
2.             1      1  1  3 
3.   1        1            2 
4.     1    1    1  1        4 
5.             1  1    1    3 
6.   1  1  1  1  1  1  1  1  1    9 
7.           1    1        2 
8.   1  1  1    1  1  1  1  1    8 
9. 1      1    1  1  1    1    6 
10.          1  1  1    1      4 
Total / 
Patient 
1  3  4  3  3  6  8  7  3  6  2   
Table 3. ACEQ# and Patient endorsement.  Patient mean 4.18 (±2.23SD)                                     
 
 




ACEQ Item % Endorsed 
1. Verbal abuse/threat 45.45% 
2. Physical abuse 27.27% 
3. Sexual abuse 18.18% 
4. Emotional neglect 36.36% 
5. Physical neglect 27.27% 
6. Parental separation 81.82% 
7. Domestic/Maternal abuse 18.18% 
8. Household alcohol/substance 
abuse 
72.73% 
9. Household mental health / 
suicide 
54.55% 
10. Household member in prison 36.36% 
Table 4. ACEQ Item % Endorsed   
 
Figure 6. Mean & SD of ACEs Scores per population.  
Every patient, (100%) endorsed at least 1 ACE. 90% endorsed ≥2 ACEs, 80% ≥3 ACEs, 
45% ≥4 ACEs, and 36% ≥6 ACEs. Total ACEQ mean was 4.18 (±2.23 SD), Women had a 
slightly higher mean of 4.50 (±2.38 SD) than men 4.00 (±2.31 SD). In women 100% endorsed ≥2 




ACEs, 75% ≥3 ACEs, and 50% ≥6 ACEs. In men 100% ≥1 ACE, 86% ≥3 ACEs, 43% ≥4 ACEs, 
and 28% ≥6 ACEs.          
Evaluation of ACEs and BDNF, β-catenin, and Cortisol 
ACEs score was assessed in relation to the expression of 3 hormones, BDNF, β-catenin, 
and cortisol. Pearson r correlation of ACEs, BDNF, β-catenin, and Cortisol. ACE and Cortisol 
demonstrate significant negative correlation (r=-0.66). BDNF and β-catenin demonstrated 
significant positive correlation (r=0.74).  
 
Figure 7. Pearson r correlation of ACEs, BDNF, β-catenin, & Cortisol.  
Simple linear regressions were performed to analyze correlation and significance. BDNF 
and β-catenin both demonstrate downward trend but were not significant (p=0.08 & p=0.18 




respectively). Cortisol demonstrated significant correlation (p=0.03). p≤0.05 for significance. The 
majority of patients were diagnosed as SzA BP. Because of the limited distribution of diagnoses 
in the limited sample size it wasn’t possible to assess ACEs versus hormones across the different 
diagnoses.  
 
Figure 8. Simple linear regression of ACEs scores versus (A) BDNF, (B) β-catenin, (C) Cortisol 
 




Populations were assessed comparing Female and Male ACE scores and hormone 
correlations. Simple linear regressions were performed to analyze correlation and significance. In 
Females BDNF and β-catenin both demonstrate downward trend but were not significant (p=0.45 
& p=0.31 respectively). Cortisol demonstrated significant correlation (p=0.02). In Males all 
demonstrate downward trend, but none were significant (p=0.089, p=0.58, p=0.15, respectively). 
 
 
Figure 9. Simple linear regression of Female ACEs scores versus (A) BDNF, (B) β-catenin, & 
(C) Cortisol. 
 
Figure 10. Simple linear regression of Male ACEs scores versus (A) BDNF, (B) β-catenin, & (C) 
Cortisol. 
Patients with UD were extracted, and ACEs and hormone correlation were assessed. 
Simple linear regression of ACE scores in only patients that indicated UD versus hormone levels. 




All demonstrated downward trends, but none were significant (p=0.16, p=0.35, p=0.12 
respectively). 
Linear regression of hormone levels versus number of UDs were performed. BDNF was 
significant for positive correlation with number of UDs (p=0.014). β-catenin demonstrated 
upward trending but was not significant (p=0.10). Cortisol indicated no correlation (p=0.77).  
Figure 11. Simple linear regression of ACEs scores in only patients that endorsed UD versus (A) 
BDNF, (B) β-catenin, & (C) Cortisol 
Figure 12. Simple linear regression of number of UDs endorsed per patient versus (D) BDNF, (E) 









Initial search generated 6,957 results, these were reviewed and included with 
confirmation of eligibility. Of these there were 170 studies that met criteria. Within these there 
were 24 instruments used alone or in combination with each other to assess childhood trauma in 
patients with psychosis. 
 
 
     Fig. 13 Study Selection PRISMA Flow Chart 
 
The instruments were isolated from each study and tallied by instrument. If a study used 
two separate instruments both were included to calculate prevalence. The Childhood Trauma 
Questionnaire (CTQ) accounted for 58.8% of studies. The Childhood Experience of Care and 




Abuse Questionnaire and Childhood Experience of Care and Abuse Interview accounted for 
approximately 18.5% of studies, at 16.7% and 1.8% respectively. The Early Trauma Inventory 
accounted for 4.7% of studies. The remaining 20 studies account for the remaining 20%. 
Instrument # Studies Prevalence 
Childhood Trauma Questionnaire (CTQ)  100 58.82% 
Childhood Experience of Care Abuse Questionnaire (CECA.Q/I)  31 18.24% 
Early Trauma Inventory (ETI)  8 4.71% 
Childhood Adversity Questionnaire (CAQ)  5 2.94% 
Maltreatment and Abuse Chronology of Exposure (MACE)  4 2.35% 
Childhood Abuse Questionnaire (CAQ)  4 2.35% 
Adverse Childhood Experiences Questionnaire (ACEQ)  3 1.76% 
Risky Families Questionnaire (RFQ)  3 1.76% 
Traumatic Experiences Checklist (TEC)  3 1.76% 
Child Abuse and Trauma Scale (CATS)  2 1.18% 
Brief Betrayal Trauma Survey (BBTS)  1 0.59% 
Childhood Experiences Questionnaire (CEQ)  1 0.59% 
Childhood Sexual Trauma Questionnaire  1 0.59% 
Child Psychological Maltreatment Scale 1 0.59% 
Childhood Traumatic Events Scale (CTES) 1 0.59% 
Scale of stressful events during childhood-adolescence 1 0.59% 
Stressful life events screening questionnaire-Revised 1 0.59% 
Structured Trauma Interview (STI) 1 0.59% 
Trauma Antecedents Questionnaire (TAQ)  1 0.59% 
Trauma History Questionnaire (THQ) 1 0.59% 























Childhood Traumatic Events Scale (CTES) 1988 1 
Structured Trauma Interview (STI) 1989 1 
Childhood Experience of Care Abuse Questionnaire/Interview (CECA.Q/I) 1994 31 
Child Abuse and Trauma Scale (CATS) 1995 2 
Childhood Trauma Questionnaire (CTQ) 1997 100 
Adverse Childhood Experiences Questionnaire (ACEQ) 1998 3 
Childhood Sexual Trauma Questionnaire 1998 1 
Childhood Abuse Questionnaire (CAQ) 1999 4 
Early Trauma Inventory (ETI) 2000 8 
Traumatic Experiences Checklist (TEC) 2002 3 
Childhood Adversity Questionnaire (CAQ) 2004 5 
Risky Families Questionnaire (RFQ) 2004 3 
Brief Betrayal Trauma Survey (BBTS) 2006 1 
Scale of stressful events during childhood-adolescence 2007 1 
Child Psychological Maltreatment Scale 2010 1 
Trauma History Questionnaire (THQ) 2011 1 
Maltreatment and Abuse Chronology of Exposure (MACE) 2015 4 
Stressful life events screening questionnaire-Revised 2016 1 
Childhood Experiences Questionnaire (CEQ) 2018 1 
Trauma Antecedents Questionnaire (TAQ) 2019 1 
Table 6. Year of Instrument of Publication 
 
 











In this study population demographic was consistent with epidemiological associations 
with SSDs. The population was predominantly male with a younger mean age for men, consistent 
with earlier onset in in men (Kahn et al., 2015). Employment is statistically low for patients with 
SSDs, with rates ranging from 10-20% (Mueser & McGurk, 2004). In this study 36.4% endorsed 
employment either full or part time. Despite employment status, they were still at or within 200% 
of the FPL, as noted in results, with the remaining 63.6% below the FPL. Socioeconomic 
hardship is strongly associated with both the incidence of ACEs and development of an SSD 








SSD, UD, and ACEs 
It is interesting to consider the predominance of the SzA diagnosis and whether that is 
indicative of the population sample, if willingness to participate is possibly more diagnosis 
dependent, or if mood disorder and psychosis are strongly comorbid. The presence of UD and 
early substance use are also associated with SSDs (Khokhar et al., 2018). Early use of cannabis, 
nicotine, and alcohol have all been studied in relation to age of onset and severity in SSDs 
(Khokhar et al., 2018). Additionally, in a study of 29 patients diagnosed with UD, 100% reported 
having at least one ACE (Chandler et al., 2018). Unfortunately, the SCID does not specifically 
screen for nicotine use or dependence. In 2018 it was estimated that 746,000 Oklahomans 18 or 
older had either Illicit Drug, Substance, Alcohol, or Painkiller Use Disorders (NSDUH, 2018). 
The population of Oklahoma is a little over 3.9 million, with just over 3 million age 18 or over. 
That means a staggering 25% of that population in Oklahoma would have a UD. According to the 
Oklahoma Department of Mental Health and Substance Abuse Services (ODMHSAS) in 2012, 
Oklahoma ranked 3rd (22.4%) in the nation for rates of Any Mental Illness and 2nd in the nation 
at 11.9% for Any Substance Abuse Disorders. They estimated that currently 700,000-950,000 
adult Oklahomans need services, and most are not receiving them (www.odmhsas.org). They 
estimated that in Tulsa county alone, almost 94,000 people over the age of 18 need mental health 
treatment and 81% of them are not receiving any. This means that of those in need of service, 
10% of them are in Tulsa county.  
Along with the high incidence of severe mental illness and substance abuse, Oklahoma 
has one of the higher incidence rates for ACEs. In previous years, Oklahoma has regularly held 
the number on spot in number of ACEs per state. According to the National Survey of Children's 
Health, U.S. Department of Health and Human Services, Health Resources and Services 
Administration (HRSA), Maternal and Child Health Bureau (MCHB), 2018-2019, Oklahoma in is 




in the top 12% for ACEs in children 0-17 years old. Meaning almost 20% of all children in 
Oklahoma under 18 have experienced two or more ACEs. The national average is 15%.  
In previous studies of ACEs and SSD, patients endorsed at least one ACE at rates of 90 – 
94% (Prokopez et al., 2018, Vallejo et al., 2016, Propokez et al., 2020). In our sample, 100% of 
the participants endorsed having at least one ACE, with 90% endorsing two, and 80% three or 
more. The mean for our study was 4.18 (±2.23 SD). In the original ACEs study, an exposure to 4 
or more ACEs was found to consistently increase odd ratios of disease presentation (Felitti et al., 
1998). ACEs exposures can be intergenerational, and a large percent of the adult population in 
general experience ACEs (Dube, 2018). We could anecdotally see ACEs reflected 
intergenerationally in our study if we look at the ACEs endorsed and their associated 
demographic and mental health indicators. For example, 64% of participants endorsed UD, and 
73% endorsed household alcohol or substance abuse. A systematic review and meta-analysis of 
the effect of multiple ACEs on health found that the outcomes of mental illness and substance 
abuse had the strongest relationships with multiple ACEs (Hughes et al, 2017). Only two of the 
study participants were married, the rest, 82%, were divorced, or single, and parental 
separation/divorce was endorsed by 82% of participants. Also 55% of participants, all of which 
had a SSD, endorsed parental mental illness/suicide. The importance of parental mental illness in 
a cohort of patients with SSD is reflected in the 1981 study by Tableman. The study indicated a 
15% likelihood of developing Schizophrenia when one parent was affected and 32% if both 
parents were affected. A meta-analysis assessed mental health outcomes of the offspring of 
parents with a severe mental illness versus controls. It indicated in incidence of severe parental 
mental illness, offspring had a 32% probability of developing a severe mental illness as adults, a 
risk that was more than double that of the control population (Rasic et al., 2014). These outcomes 
support the perpetuation of intergenerational ACEs by increasing likely exposure to ACEs in the 
form of parental domestic violence, mental illness, and substance use (Hughes et al, 2017). 




ACEs and BDNF, β-catenin, and Cortisol 
In ACEs regressions with BDNF, β-catenin, and cortisol, all saw downward trends with 
cortisol demonstrating significance. The decreased hormone levels with increase in ACEs score 
was hypothesized. In power analysis, increased downward trend to significance is projected in 
both BDNF and β-catenin with an increase in n.  
Significant cortisol levels in our pilot data suggest that cortisol is not affected by 
antipsychotic medication or substance use as appears to be the case with BDNF and β-catenin. 
Both BDNF and β-catenin levels have been noted to increase with antipsychotic medications 
(Green et al., 2011, Sutton et al., 2007). BDNF levels have also been shown to be modulated by 
substance use. In the instance of methamphetamine use, there has been shown to be significant 
increase in BDNF expression while cannabis use showed no significant difference in BDNF 
expression (Ornell et al., 2018) when compared to controls in an extensive meta-analysis. It 
demonstrated significant decrease in BDNF in alcohol abuse versus controls across multiple 
studies from the same meta-analysis (Ornell et al., 2018). Within our study there is a significant 
positive correlation with the number of UDs endorsed and BDNF levels. β-catenin levels showed 
an upward trend in relation to the number of UDs. Finally, cortisol showed no modulation 
associated with substance use. Interestingly, cortisol showed no trend to correlation at all with the 
number of UDs, supporting speculation that UD may be a confounding factor in the levels of 
DNF and β-catenin expressed.  





Figure 14. β-catenin correlation to BDNF.  
The regulation and expression of both BNDF and β-catenin appears to be affected 
concomitantly, given the upregulating effect β-catenin has on BDNF their coupled expression is 
not improbable. This is true especially in relation to the tight correlation demonstrated in this 
study between the two, p=0.0092. There was no obvious relationship between either BNDF or β-
catenin and cortisol. A negative correlation was expected given cortisols’ regulatory association 
with both.  
 
 





There are many instruments available to assess childhood trauma. In this review, there 
are two studies that have significantly greater use of the CTQ and the CECAQ/I.  We believe this 
may be explained by the availability of the instrument proximal to the release of the major ACEs 
study by Filetti et al. in 1998. The instruments existed and had been used prior to the study’s 
release, CTQ 1997 and CECA 1994, lending them an existing credibility in the fast-growing 
field. In review, there are only three other instruments that were identified in use prior to 1998, 
two of those being close to a decade older used in one study and the other, the CATS in 1995, 
was identified in two studies. 
The attempt to further develop a tool to assess childhood trauma explains the number of 
instruments developed following the ACEs study’s release and the somewhat disparate use 
throughout assessments. Clearly, the importance of assessment is demonstrated as well as the 














We expected to see downward trend in all biomarkers as the severity of the ACEs score 
increased. This study indicated that the expectation, though not wholly met, could be seen with an 
expanded study and the data are encouraging.  
The systematic review highlighted the large number of instruments available However, it 
clearly illuminated that the CTQ may be a potential standard worth modifying or with an adjunct 
in future studies to affirm psychometric viability as well as inclusiveness of assessment criteria. 
  
SSDs, ACEs, BDNF, β-catenin, and Cortisol 
In general, the data we collected is consistent with existing data. In SSDs there is a 
greater than 90% probability of having one or more ACE. A mean of 4 ACEs in this population is 
consistent with SSD and UD, as well as socioeconomic status.  
While only cortisol was significant, this study is strongly supportive that all three 
hormones are related to ACEs distribution. With an increase in sample size, significance is likely 
to be found in BDNF and β-catenin, as well as cortisol. Our sample is small, n=11, and while




effective as a pilot, larger power studies are needed to demonstrate results with greater clarity. 
Looking into the study on a larger scale is an important future direction.  
It is very exciting to contribute to the developing interest in the association of β-catenin 
and SSD as a more novel aspect of this study. Especially considering the strong relationship that 
BDNF and β-catenin have to each other, and the ability of β-catenin to upregulate BDNF. It 
continues to be of interest to examine the possible downregulation of both via cortisol. It would 
be of interest to examine cortisol, BDNF, and β-catenin levels over time in individuals, as well as 
in monitoring treatment progress. 
 
Systematic Review 
The CTQ is the most widely utilized measure of childhood trauma. It encompasses 
physical, emotional, sexual abuse/neglect, and socioeconomic hardship. It allows the taker to 
quantify the degree to which the experience affected them. The psychometric properties of the 
CTQ have been extensively analyzed in multiple reviews (Roy & Perry, 2004, Saini et al., 2019, 
Matheson et al., 2013, and Hulme, 2009). 
There are many aspects of the childhood trauma instrument that can be followed up on 
from this study. There is potential to do analysis of instrument criteria assessed, the relevance of 
childhood trauma type reported in relation to psychosis, schizophrenia, or schizoaffective 
disorder per instrument, how strong/consistent is the correlation indicated per instrument. 
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APPENDIX B: IRB #2020021 Recruitment Script 
Participants were screened via onsite nursing staff to facilitate ease in assessing criteria for 
inclusion. Following positive recruitment assessment from nursing staff and willingness to 
participate, research staff were introduced to patient and informed consent was explained and 
acquired. 
During intake assessment: 
• Patient may qualify if they meet the following criteria:  
o Between the ages of 18-64 
o Current diagnosis and treatment of schizophrenia, schizophreniform disorder or 
schizoaffective disorder 
o Has completed at least 8 years of formal education 
o Speaks and reads English fluently 
o Does not have a proxy for medical decision-making, legal guardian, or been 
otherwise determined unable to give consent 
o Is current and compliant on antipsychotic medications 
o IQ >70 or no previous diagnosis of intellectual disability 
o No past diagnosis or suspected current diagnosis of a neurodevelopmental 
disorder (e.g., autism, learning disability) or neurocognitive disorder (e.g., 
dementia) 
o No history of major head trauma (defined as loss of consciousness for 30 minutes 
or longer) or brain surgery (Note: History of concussion, including brief loss of 
consciousness, is okay)  
o No history of psychosis secondary to a medical condition or diagnosis of 
psychosis secondary to substance abuse 
o No history of presence of endocrine conditions that would alter prolactin or 
cortisol levels, such as Prolactinoma or Cushings’ respectively 
o If female, is not pregnant or lactating 
• If they meet the above criteria, give them a flier and tell them: 
Recruitment Scripts 
“Some OSU researchers are doing a study to see how people’s life experiences may change the 
amount your brain manufactures certain brain chemicals. You may qualify to participate. Here is 
a flier with some more information. Someone from the research team can give you some more 
information about it. if you are interested” 
Research Staff, initial patient contact: 
• “Hi, I’m __________, a researcher from OSU. Your doctor might have given you a flier 
about the research project that we are doing here at FCS and I would like to tell you a 
little bit more about it if you are interested in hearing more. 
• “We’re interested in seeing how different aspects of people’s brain functioning might 
change when they have been diagnosed with schizophrenia and exposed to certain 




• childhood life experiences. To do this, people are given mental health diagnostic test, and 
fill out a short self-answered survey about those childhood experiences. We’re also 
interested in chemical changes that might be happening in the brain at the same time, so 
we take some small blood samples to test as well.”  
• Answer any questions the person has at this point. 
• “If you think you might be interested, I just need to ask you a few questions to make sure 
that you would qualify. Then I can go over the rest of the details and you can decide if 
you would like to participate.” 
• Check that the person meets all of the inclusion criteria: 
o Between the ages of 18-64 
• Date of birth __/__/_____ 
o Current diagnosis of schizophrenia, schizophreniform disorder or schizoaffective 
disorder 
• Do you have a current diagnosis of one of schizophrenia, 
schizophreniform disorder or schizoaffective disorder?  
• Y or N 
o Has completed at least 8 years of formal education 
• What is the highest grade level you have completed? ______ 
o Speaks and reads English fluently 
• Is English your first language or do you consider yourself fluent in 
English? 
• Y or N 
o Does not have a proxy for medical decision-making, legal guardian, or been 
otherwise determined unable to give consent 
• Is there someone other than yourself that is responsible for making 
your medical decisions? 
o Is current and compliant on antipsychotic medications. 
• Are you current and compliant with your antipsychotic medications? 
• Y or N 
o IQ >70 or no previous diagnosis of intellectual disability 
• Have you ever been previously diagnosed with an intellectual 
disability? 
• Y or N 
o No past diagnosis or suspected current diagnosis of a neurodevelopmental 
disorder (e.g., autism, learning disability) or neurocognitive disorder (e.g., 
dementia) 
• Do you have past or present diagnosis of a neurodevelopmental 
disorder (e.g., autism, learning disability) or neurocognitive disorder 
(e.g., dementia)? 
• Y or N 
o No history of major head trauma (defined as loss of consciousness for 30 minutes 
or longer) or brain surgery. (Note: History of concussion, including brief loss of 
consciousness, is okay 
• Do you have a history of major head trauma (defined as loss of 
consciousness for 30 minutes or longer) or brain surgery? 
• Y or N 
• History of concussion, including brief loss of consciousness, is 
okay  




o No history of psychosis secondary to a medical condition or diagnosis of 
psychosis secondary to substance abuse. 
• Do you have a history of psychosis secondary to a physical medical 
condition or diagnosis of psychosis secondary to substance abuse? 
• Y or N 
o No history of presence of endocrine conditions that would alter prolactin or 
cortisol levels, such as Prolactinoma or Cushings’ respectively 
• Do you have a history of any endocrine conditions such as a 
Prolactinoma or Cushing’s? 
• Y or N 
o If female, is not pregnant or lactating 
• Are you currently pregnant or lactating? 
• Y or N 
• If criteria are met, verbally summarize each section of the consent form, allow the person 
time to read each page and initial when done. Answer all questions as they arise. 
Complete signature block.




APPENDIX C: IRB #2020021 Informed Consent 
OKLAHOMA STATE UNIVERSITY  
Center for Health Sciences 
PARTICIPANT INFORMATION AND CONSENT FORM 
Title of Project: BDNF, beta-catenin, and cortisol serum levels correlated with severity of 
Adverse Childhood Experiences (ACEs) Questionnaire score in patients diagnosed with 
schizophrenia spectrum disorder. 
Investigators: Rebecca Gaglia, BA, MS2, Biomed PhD Candidate  
Jason Beaman, DO., MS., MPH., FAPA  
Department of Psychiatry & Behavioral Sciences 
Department of Biomedical Sciences 
Oklahoma State University-Center for Health Sciences 
gaglia@okstate.edu, jason.beaman@okstate.edu  
“You” refers to the participant. 
“We” refers to the research team at Oklahoma State University-Center for Health Sciences. 
You are being offered the opportunity to take part in this research study because you are receiving 
psychiatric treatment at Family and Children Services (FCS). This research is being done to study 
the association of childhood trauma and selected biomarkers in patients diagnosed with 
schizophrenia spectrum disorder.  
What you should know about participating in a research study: 
Participation in research is a voluntary choice, and this consent form will provide you with 
information about the risks, benefits or alternatives to participation in the study. 
• Someone will explain this research study to you. 
• You may volunteer to be in the research study. 
• Whether or not you take part is up to you. 
• You can choose not to take part in the research study. 
• You can agree to take part now and later change your mind. 
• Whatever you decide it will not be held against you. 
• Feel free to ask all the questions you want before you decide.




Who can you talk to? 
Although this consent form provides detailed information about this study, a research team 
member is available to answer any questions you may have about this study and/or participation 
in it. If you have questions, concerns, or complaints, or think the research has hurt you, talk to the 
researcher or identified members of the research team at (phone number). 
This research has been reviewed and approved by the Oklahoma State University Center for 
Health Sciences Institutional Review Board (IRB). You may contact the chairperson of this 
committee at 918-561-1400 or chsirb@okstate.edu for any of the following: 
• Your questions, concerns, or complaints are not being answered by the researcher or 
research team. 
• You cannot reach the researcher or a member of the research team. 
• You want to talk to someone other than the researcher or the research team. 
• You have questions about your rights as a research participant. 
• You want to get information or provide input about this research or your experience in 
this research study. Why are we doing this research? 
The purpose of the research is to study the association of childhood trauma and selected 
biomarkers.  
How long will the research last? 
We expect that you will be in this research study for 1 day. You will have 1 study appointment 
that will last about 1 hour.  
How many people will be studied? 
We expect about 10-20 people to be enrolled into this study. 
What happens if you say yes, you want to be in this research? 
You will be asked to complete 2 different types of activities. These will all take place at FCS: 
1. Structured Clinical Interview DSM-5-CV: you will be administered a clinical interview 
to confirm psychiatric diagnosis for inclusion in the study. This will take 30-45 minutes 
to complete. 
2. Adverse Childhood Experience Questionnaire: you will be asked to complete one self-
report surveys that asks about experiences in childhood. This will take about 7-10 
minutes to complete. 
3. Blood Sample: you will be asked to give 8mL of blood to study some of the chemical 
markers that are related to childhood trauma and schizophrenia.  
What happens if you say no, you do not want to be in this research? 
You may decide not to take part in the research, and it will not be held against you. A refusal to 
participate in this research study will involve no penalty or loss of benefits to which you are 
otherwise entitled. 
What happens if you say yes, but you change your mind later? 




You can agree to take part in the research now and stop at any time. It will not be held against 
you. If you want to stop your participation in the study, you may tell one of the investigators or 
another OSU research team member at FCS, verbally or in writing that you no longer want to 
participate. Stopping participation will not result in penalty or loss of benefits to which you are 
otherwise entitled. However, you will not be paid the full amount of the study compensation if 
you do not complete all of the activities.  
If you stop participating in the research study, data already collected may not be removed from 
the study database.  
Is there a risk to being in this study? 
Participation in this study may involve risks or discomforts. These include the following:  
• It is possible that you may become frustrated, bored, or tired during the Structured Clinical 
Interview. You may take a break and/or stop at any time. 
• It is possible that the questions being asked about your childhood may make you feel 
uncomfortable. You may skip questions that make you feel uncomfortable. 
• You may experience slight pain when the needle is inserted for the blood draw. There is a 
small risk of bruising and/or infection at the site. It is possible that a participant may feel 
lightheaded, nauseated, or faint. 
• There is possible risk for loss of confidentiality. We have several measures in place to 
keep your study information private, including using code numbers instead of names on 
study documents whenever possible, password-protecting all electronic data files, and 
storing other materials in locked cabinets, but it may still be possible for some of the 
information collected to become known outside of this research setting. Some of this 
information, could negatively affect your personal reputation, your ability to get a job, or 
have other unknown outcomes. 
• In addition to these risks, this research may harm you in ways that are unknown and 
unforeseeable. If we learn of new risks that we think might affect your desire to stay in 
the research, we will tell you. If major risks are discovered after the study is finished, it is 
possible that the sponsor may attempt to contact you. 
What benefits can be reasonably expected? 
There is no expected direct benefit to you for participating in this study. The researchers, 
however, may learn more about childhood trauma, biomarkers and development of schizophrenia. 
Such understanding may assist in the creation of better diagnosis, treatment procedures, and early 
interventions for patients with or at risk for the development of schizophrenia spectrum disorders. 
Will it cost you anything to be in this study? 
There is no cost to you for taking part in this research study.  
Will you be compensated for participating in this study? 
If you agree to take part in the research study, FCS will provide you with $10 QT prepaid gift 
card following completion of all study activities.   
What are your responsibilities? 
Tell the researcher or research study staff about any changes in recent medication or medication 
compliance. 




What happens to the information we collect? 
Efforts will be made to limit sharing of your personal information, including study data and 
medical records, to people who have a need to review this information. We cannot promise 
complete confidentiality. Organizations that may inspect and copy your information for quality 
assurance and data analysis include: 
• The Researcher and his/her research staff 
• Oklahoma State University staff or its agents 
• The IRB and staff 
We may publish the results of this research. However, we will keep your name and other 
identifying information confidential and anonymous in any presentations or publications. 
We do not intend to share any individual results with you, should you wish to receive a summary 
of your study results you may contact the PI and a summary will be sent once the information is 
available.  
Use of your blood samples 
The blood samples that are collected for this study may be stored for years in what is called a 
“biobank” that may be used by scientists in the future to study other questions that arise due to 
new scientific or technological advances.  
• The samples will be stored with only a unique code and will not have your name or other 
identifying information.  
• It is possible that your blood sample may be used in the future for commercial profit. You 
will not share in this commercial profit. 
• Research using your blood will not include whole genome sequencing. 
Federal law provides additional protections of your personal information. These are described in a 
later section (HIPAA Authorization for Release of Health Information for Research Purposes). 
Can you be removed from the research without your permission? 
The investigators can remove you from the research study without your approval. Possible 
reasons for removal include: 
• If you have recent changes in medication or medication compliance 
• If you do not keep appointments 
• If the researcher or FCS treatment team considers it in your best interest  
• The investigator (or sponsor) can also end the research study early 
HIPAA Authorization for Release of Health Information for Research Purposes & 
Authorization for Release of Confidential Substance Use Disorder Patient Records 
The Health Insurance Portability and Accountability Act (HIPAA) allows a hospital or doctor’s 
office to use or release protected health information (PHI) for the purposes of treatment, payment 
or health care operations. Health care operations activities include such things as audits, quality 
assurance initiatives, audits from insurance companies, treating physicians, legal advisors, 
insurers and data storage companies. 




This HIPAA authorization gives permission from you to use or release your PHI for research 
purposes. A HIPAA authorization is in addition to your consent to participate in this research 
study. 
What will be done with your protected health information? 
Your protected health information (PHI) will be collected through on-site access and review of 
your FCS treatment records and entered in a database along with the information from other 
people taking part in this study. 
Why are you being asked to release it? 
Your protected health information (PHI) will be used for study eligibility, for contact purposes, 
and to help us understand the association of childhood experience and selected biomarkers in 
patients diagnosed with schizophrenia spectrum disorders. 
What will be released? 
To complete this research study, we will need to collect and release (disclose) information about 
you. This information includes:  
• Your contact information and insurance status for treatment payment 
• Your medical and psychiatric diagnoses 
The information authorized for release may include records which may indicate the presence 
of a communicable or venereal disease which may include, but are not limited to, diseases 
such as hepatitis, syphilis, gonorrhea and the human immunodeficiency virus also known as 
Acquired Deficiency Syndrome (AIDS). [63 O.S. § 1-1502 (B)] 
Who will use it or share it? 
• The researcher and her research study staff 
• Oklahoma State University staff or its agents 
• The IRB and staff 
• The Sponsor(s) of the research or its agents (monitors, auditors) 
Once your protected health information (PHI) has been disclosed it is possible that anyone who 
receives that information may re-disclose it. Because some of these individuals who receive your 
PHI may not be required by law to keep your information confidential, we cannot guarantee that 
your information will not be released or made available to another party once it leaves Oklahoma 
State University. Therefore, we share your information only if necessary and we use all 
reasonable efforts to request that those individuals who receive your information take steps to 
protect your privacy. 
How long will this authorization last? 
This authorization has no expiration date. 
Can you stop your protected information (PHI) from being used? 
You can tell us to stop collecting health information that can be traced to you at any time unless 
action has already been taken based upon this consent. We will stop, except in very limited cases 




if needed to comply with law, protect your safety, or make sure the research was done properly. If 
you have any questions about this, please ask. 
If you want us to stop using PHI, you must tell us in writing. Write or email Rebecca Gaglia at 
gaglia@okstate.edu or 1111 W. 17th Street, Tulsa, OK 74107. 
What happens if you do not want us to collect your personal health information (PHI)? 
If you decide not to authorize release of your protected health information (PHI) to be used as 
part of this study, your decision will in no way affect your medical care or cause you to lose any 
benefits to which you are entitled. You cannot participate in this research study if you do not 
authorize the use or release of your PHI. 
When will it be destroyed? 
We do not know when your information will no longer be used therefore the information will be 
kept for an indefinite length of time. The minimum amount of time it will be retained is 3 years 
after the completion of the final study report. The Primary Investigator, Rebecca Gaglia, will be 
responsible for destroying the data. 
Do not sign this consent form until you have had a chance to ask questions and have received 
satisfactory answers to all of your questions. 
Signature Block for Capable Adult: Long Form 
Your signature below documents your consent to take part in this research and 
to the use and disclosure of your protected health information, as specified in 
this consent form. Signing this authorization will not affect your eligibility for 
benefits, treatment, enrollment, or payment of claims. 
I understand that upon my request I will be provided with a list of agencies that 
my information has been disclosed to. I understand that treatment services are 
not contingent upon or influenced by my free and voluntary decision 
concerning authorization of the release of information. I understand that the 
information disclosed as a result of this consent may be subject to redisclosure 
by the recipient and may no longer be protected by federal regulations.   
You will receive a signed copy of this complete form. 
 
  
Signature of participant Date 
  
Printed name of participant  
  
Signature of person obtaining consent Date 
  
Printed name of person obtaining consent  
 




APPENDIX D: IRB #2020021 Participant Data Sheet 
Demographic Information  




Ethnicity (Optional) Select all that apply 
• American Indian or Alaska Native 
• Asian 
• Black or African American 
• Hispanic or Latino 
• Native Hawaiian or Other Pacific Islander 
• White 
• Other __________________ 
Education Highest Level Completed (Optional) 
• High School / GED 
• Some Undergraduate Education 
• Trade Degree / Certification 
• Associate’s Degree 
• Bachelor’s Degree 
• Some Graduate Education 
• Graduate / Professional Degree 
Military Service (Optional) 
• Yes 
• No 






Occupation Status (Optional) 
• Unemployed 
• Employed PT 
• Employed FT 
• Student FT 
• Student PT 
Annual Income (Optional) 
• $0 - $10,000 
• $10,000 - $35,000 
• $35,000 - $60,000 
• $60,000 - $85,000 
• $85,000 - Above





APPENDIX E: IRB #2020021 ACEQ 
http://www.odmhsas.org/picis/ACE.pdf 
Adverse Childhood Experience (ACE) Questionnaire 
Finding your ACE Score While you were growing up, during your first 18 years of life: 
1. Did a parent or other adult in the household often …Swear at you, insult you, put you 
down, or humiliate you? Or Act in a way that made you afraid that you might be 
physically hurt? 
Yes No If yes enter 1 ________ 
2. Did a parent or other adult in the household often …Push, grab, slap, or throw 
something at you? Or Ever hit you so hard that you had marks or were injured? 
Yes No If yes enter 1 ________ 
3. Did an adult or person at least 5 years older than you ever…Touch or fondle you or 
have you touch their body in a sexual way? Or Try to or actually have oral, anal, or 
vaginal sex with you? 
Yes No If yes enter 1 ________ 
4. Did you often feel that …No one in your family loved you or thought you were 
important or special? Or Your family didn’t look out for each other, feel close to each 
other, or support each other? 
Yes No If yes enter 1 ________ 
5. Did you often feel that …You didn’t have enough to eat, had to wear dirty clothes, and 
had no one to protect you? Or Your parents were too drunk or high to take care of you or 
take you to the doctor if you needed it? 
Yes No If yes enter 1 ________ 
6. Were your parents ever separated or divorced? 
Yes No If yes enter 1 ________ 
7. Was your mother or stepmother: Often pushed, grabbed, slapped, or had something 
thrown at her? Or Sometimes or often kicked, bitten, hit with a fist, or hit with something 
hard? Or Ever repeatedly hit over at least a few minutes or threatened with a gun or 
knife? 
Yes No If yes enter 1 ________ 
8. Did you live with anyone who was a problem drinker or alcoholic or who used street 
drugs? 
Yes No If yes enter 1 ________




9. Was a household member depressed or mentally ill or did a household member attempt 
suicide? 
Yes No If yes enter 1 ________ 
10. Did a household member go to prison? 
Yes No If yes enter 1 ________ 
Now add up your “Yes” answers: _______ This is your ACE Score. 




APPENDIX F: IRB #2020021 SCID 
The Structured Clinical Interview for DSM-5, Clinician Version (SCID-5-CV), is a semistructured 
interview for making the DSM-5 diagnoses. It is administered by a clinician or trained mental 
health professional who is familiar with the DSM-5 classification and diagnostic criteria. This 
was used to establish a diagnosis of schizophrenia or schizoaffective disorder with uniform 
diagnostic criteria, in an effort to eliminate subjective diagnostic bias. Research PI, Rebecca 
Gaglia, administered all SCID interviews for consistency. SCID results were reviewed with 























APPENDIX G: BDNF ELISA Protocol 
Standard curve in duplicate. 
All Serum Samples in septuplicate. 
All materials and prepared reagents brought room temperature prior to use.   
1. Prepare 1X Wash Buffer. 
a. 20mL Wash Buffer Conc 
b. 380mL Distilled (DI) water 
c. Agitate solution. 
2. Prepare 1X Assay Diluent B 
a. 15mL Assay Diluent B Conc 
b. 75mL DI water 
3. Prepare Standard Dilutions - Using Assay Diluent A for Serum Samples 
a. Label tubes for Standard dilutions 
i. Std1: 16ng/mL 
ii. Std2: 6.4ng/mL 
iii. Std3: 2.56ng/mL 
iv. Std 4: 1.02ng/mL 
v. Std 5: 0.41ng/mL 
vi. Std 6: 0.16ng/mL 
vii. Std 7: 0.066ng/mL 
viii. Std8/Blank: 0ng/mL 
b. Spin vial BDNF Standard 
c. Pipette 720𝜇𝜇L Assay Diluent A into standard vial, gently vortex 10sec 
d. Pipette 960𝜇𝜇L Assay Diluent A into Std1 tube 
e. Pipette 300𝜇𝜇L into Std2 - 8 tubes 
f. Pipette 40𝜇𝜇L in Std1 vial 
g. From Std1 make serial dilutions of 200𝜇𝜇L through Std7 
4. Prepare Serum Sample Dilutions 1:200 - Using Assay Diluent A for Serum Samples 
a. Pipette 4𝜇𝜇L per Serum Sample to corresponding labeled vial.  
b. Pipette 800𝜇𝜇L Assay Diluent A per sample 
c. Vortex each sample gently for 7 seconds 
5. Plate Binding Incubation 
a. Pipette 100𝜇𝜇L of each standard and sample into designated wells 
b. Cover and incubate 2.5 hours at room temp with shaking.




6. Prepare 1X Biotinylated anti-Human BDNF Detector Antibody for Step 8 
a. Vortex both Biotinylated anti-Human BDNF Detector Antibody vials 10 seconds 
b. Biotinylated anti-Human BDNF Detector Antibody Conc 
i. Pipette 100𝜇𝜇L 1X Assay Diluent B into each vial  
ii. Vortex each vial 10 seconds 
c. 1X Biotinylated anti-Human BDNF Detector Antibody 
i. Pipette 100𝜇𝜇L from each vial (200𝜇𝜇L total) 
ii. Add to 16mL 1X Assay Diluent B 
iii. Gently agitate. 
7. Wash  
a. Discard the solution and wash 4 times with 1X Wash Solution. Wash by filling 
each well with 1X Wash Solution (min 300𝜇𝜇L) using disposable graduated 
pipette. Removal of liquid at each step by decanting. After the last wash decant, 
invert the plate and blot against clean paper towels.  
8. 1X Biotinylated anti-Human BDNF Detector Antibody Incubation 
a. Add 100𝜇𝜇L of 1X Biotinylated anti-Human BDNF Detector Ab to each well.  
b. Incubate 1 hour at room temperature with shaking.  
9. Prepare 1X HRP-Streptavidin solution for Step 11. 
a. Vortex HRP-Streptavidin Conc vial 10 seconds 
b. Pipette 50𝜇𝜇L HRP-Streptavidin Conc 
c. Add to 10mL 1X Assay Diluent B 
d. Vortex 20 sec 
10. Wash 
a. Discard the solution and wash 4 times with 1X Wash Solution. Wash by filling 
each well with 1X Wash Solution (min 300𝜇𝜇L) using disposable graduated 
pipette. Removal of liquid at each step by decanting. After the last wash decant, 
invert the plate and blot against clean paper towels.  
11. 1X HRP-Streptavidin solution Incubation 
a. Add 100𝜇𝜇L of prepared 1X HRP-Streptavidin solution to each well. 
b. Incubate 45 minutes at room temperature with shaking. 
12. Wash 
a. Discard the solution and wash 4 times with 1X Wash Solution. Wash by filling 
each well with 1X Wash Solution (min 300𝜇𝜇L) using disposable graduated 
pipette. Removal of liquid at each step by decanting. After the last wash decant, 
invert the plate and blot against clean paper towels.  
13. TMB Incubation 
a. Add 100𝜇𝜇L of TMB One-Step Substrate Reagent to each well. 
b. Incubate for 30 minutes at room temperature in the dark with gentle shaking.  
14. Stop Solution 
a. Add 50𝜇𝜇L of Stop Solution to each well.  
b. Read at 450nm and 550nm immediately within 30 minutes of Stop Solution.  
15. Read the plate and generate the standard curve.  
a. Read at 450nm and 550nm. 




b. Subtract 550nm values from 450nm values to correct for optical imperfections. 
c. Calculate the mean value of the duplicate readings for each standard and samples 
in septuplet.  
d. To generate a standard curve, plot the graph using the standard concentrations on 
the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. 
The best-fit line was determined by regression analysis using four parameter 
logistic curve-fit.  
e. Determine the unknown sample concentration from the Standard Curve and 
multiply the value by the dilution factor.




APPENDIX H: Beta-Catenin ELISA Protocol 
Standard curve in duplicate. 
All Serum Samples in non-diluted sextuplicate - except A2 serum quantity limited to 
quintuplicate. 
All Standard Dilutions provided in kit. 
All materials and prepared reagents brought room temperature prior to use.   
1. Prepare 1X Wash Solution. 
a. 10mL Wash Solution Conc 
b. 990mL Distilled (DI) water 
c. Agitate solution. 
2. Plate Binding Incubation 
a. Pipette 50𝜇𝜇L of each standard and sample into designated wells 
b. Add 50𝜇𝜇L of PBS to Blank Control wells 
c. Pipette 100𝜇𝜇L of Enzyme Conjugate to each well, excluding blank control wells. 
d. Cover and incubate 1 hours at room temp with shaking. 
3. Wash  
a. Discard the solution and wash 5 times with 1X Wash Solution. Wash by filling 
each well with 1X Wash Solution (min 300𝜇𝜇L) using disposable graduated 
pipette. Removal of liquid at each step by decanting. After the last wash decant, 
invert the plate and blot against clean paper towels.  
4. Substrate A and B Incubation 
a. Add 50𝜇𝜇L of Substrate A to each well. 
b. Add 50𝜇𝜇L of Substrate B to each well. 
c. Cover and incubate for 15 to no more than 30 minutes at room temperature.  
5. Stop Solution 
a. Add 50𝜇𝜇L of Stop Solution to each well.  
b. Read at 450nm immediately. 
6. Read the plate and generate the standard curve.  
a. Read at 450nm.  
b. All Opitcal Density (OD) values are subtracted by the mean of the blank control 
wells prior to result interpretation. 
c. Calculate the mean value of the duplicate readings for each standard and sample 
replicates.  
d. To generate a standard curve, plot the graph using the standard concentrations on 
the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. 




e. The best-fit line was determined by regression analysis using four parameter 
logistic curve-fit.  
f. Determine the unknown sample concentration from the Standard Curve. 




APPENDIX I. Cortisol ELISA Protocol 
Standard curve in duplicate. 
All Serum Samples in septuplicate. 
All materials and prepared reagents brought room temperature prior to use.  
1. Prepare 1X Wash Buffer. 
a. 15mL Wash Solution Conc 
b. 285mL Distilled (DI) water 
c. Agitate solution. 
2. Prepare 1X Assay Buffer. 
a. 14mL Assay Buffer Conc 
b. 56mL DI water 
c. Agitate solution. 
3. Prepare Standard Dilutions - Using 1X Assay Buffer. 
a. Label tubes for Standard dilutions: 
i. Std1: 3,200pg/mL 
ii. Std2: 1,600pg/mL 
iii. Std3: 800pg/mL 
iv. Std 4: 400pg/mL 
v. Std 5: 200pg/mL 
vi. Std 6: 100pg/mL 
vii. Std 7: 50pg/mL 
viii. Std8/Blank: 0pg/mL 
b. Pipette 450𝜇𝜇L 1X Assay Buffer into Std1 tube 
c. Pipette 250𝜇𝜇L 1X Assay Buffer into Std2 - 8 tubes 
d. Pipette 50𝜇𝜇L in Std1 tube 
e. From Std1 make serial dilutions of 250𝜇𝜇L through Std7 
4. Prepare Serum Sample Dilutions 1:100 - Using 1X Assay Buffer.  
a. Pipette 5𝜇𝜇L Dissociation Reagent into tube 
b. Pipette 5𝜇𝜇L per Serum Sample to corresponding labeled tube.  
c. Pipette 490𝜇𝜇L 1X Assay Buffer per sample 
d. Vortex each sample gently for 7 seconds 
5. Conjugate & Antibody Incubation 
a. Add 50 μL of standards or samples to the appropriate wells.  
b. Add 75 μL 1X Assay Buffer into wells for detecting non-specific binding (NSB).  
c. Add 25 μL of Cortisol Conjugate to each well.  
d. Add 25 μL of Cortisol Antibody to each well except NSB wells. 




e. Tap the side of the plate to mix. 
f. Cover and incubate 1 hour at room temperature with shaking.  
6. Wash  
a. Discard the solution and wash 4 times with 1X Wash Solution. Wash by filling 
each well with 1X Wash Solution (min 300𝜇𝜇L) using disposable graduated 
pipette. Removal of liquid at each step by decanting. After the last wash decant, 
invert the plate and blot against clean paper towels.  
7. Chromogen Incubation 
a. Add 100 μL TMB Substrate to each well.  
b. Incubate for 30 minutes at room temperature.  
8. Stop Solution 
a. Add 50 μL Stop Solution to each well.  
b. Tap side of the plate gently to mix.  
c. Read at 450nm within 10 minutes of Stop solution. 
9. Read the plate and generate the standard curve.  
a. Read the absorbance at 450 nm.  
b. Use curve-fitting software to generate the standard curve. A four-parameter 
algorithm provides the best standard curve fit.  
c. The background absorbance is subtracted from all data points, including 
standards, unknowns and controls, prior to plotting.  
d. Read the concentrations for unknown samples and controls from the standard 
curve. Multiply value(s) obtained for sample(s) by the appropriate factor to 
correct for the sample dilution. 
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